Check for updates

OPEN ACCESS

EDITED BY Zewen Kelvin Tuong, The University of Queensland, Australia

REVIEWED BY Ana-Maria Cujba, Wellcome Sanger Institute (WT), United Kingdom Chuan-Hsin Yin, Helmholtz Pioneer Campus, Germany

*CORRESPONDENCE Gang Du 1730951693@qq.com Hongtao Wang Wanghongtao001@126.com

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION This article was submitted to Systems Immunology, a section of the journal Frontiers in Immunology

RECEIVED 06 August 2022 ACCEPTED 27 February 2023 PUBLISHED 26 April 2023

CITATION

Li Z, Huang L, Li J, Yang W, Li W, Long Q, Dai X, Wang H and Du G (2023) Immunological role and prognostic value of the SKA family in pan-cancer analysis. *Front. Immunol.* 14:1012999. doi: 10.3389/fimmu.2023.1012999

COPYRIGHT

© 2023 Li, Huang, Li, Yang, Li, Long, Dai, Wang and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Immunological role and prognostic value of the SKA family in pan-cancer analysis

Zhengtian Li^{1†}, Lanying Huang^{2†}, Jiachen Li³, Wenkang Yang³, Weichao Li¹, Qiuzhong Long¹, Xinyu Dai¹, Hongtao Wang^{1*} and Gang Du^{1*}

¹Department of Bone and Joint Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, ²Department of Rehabilitation Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, ³Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Background: The spindle and kinetochore associated (SKA) complex, which plays important roles in proper chromosome segregation during mitosis by maintaining the stabilization of kinetochore-spindle microtubule attachment during mitosis, has recently been reported to exert regulatory effects on the initiation and progression of various human cancer types. Nevertheless, the prognostic significance and immune infiltration of the SKA family across cancers have not been well elucidated.

Methods: Using data from three large public datasets, including The Cancer Genome Atlas, Genotype-Tissue Expression, and Gene Expression Omnibus databases, a novel scoring system (termed the SKA score) was developed to quantify the SKA family level across cancers. We then evaluated the prognostic impact of the SKA score on survival and assessed the effect of the SKA score on immunotherapy at the pan-cancer level using multiomics bioinformatic analyses. The correlation of the SKA score and the tumor microenvironment (TME) was also explored in depth. Potential small molecular compounds and chemotherapeutic agents were assessed by CTRP and GDSC analyses. Immunohistochemistry was performed to verify the expression of the SKA family genes.

Results: Our results demonstrated a close correlation between the SKA score and tumor development and prognosis in multiple cancers. The SKA score was positively related to cell cycle pathways and DNA replication across cancers, such as E2F targets, the G2M checkpoint, MYC targets V1/V2, mitotic spindles and DNA repair. Additionally, the SKA score was negatively related to the infiltration of various immune cells with antitumor effects in the TME. In addition, the potential value of the SKA score was identified to predict immunotherapy response for melanoma and bladder cancer. We also demonstrated a correlation between SKA1/2/3 and the response to drug treatment across cancers and the promising potential of the SKA complex and its genes as therapeutic targets in cancer. Immunohistochemistry demonstrated that the expression differences of SKA1/2/3 were significant between the breast cancer group and the paracancerous group.

Conclusion: The SKA score plays a critical role in 33 cancer types and is highly related to tumor prognosis. Patients with elevated SKA scores have a clear immunosuppressive TME. The SKA score may serve as a predictor for patients receiving anti-PD-1/L1 therapy.

KEYWORDS

SKA family, pan-cancer, prognosis, tumor microenvironment, immunotherapy response

Introduction

SKA1, along with SKA2 and SKA3, constitutes the spindle- and kinetochore-associated subunit complex. The SKA family is an indispensable element that stabilizes spindle microtubules attaching to the kinetochore (KT) and ensures the completion of the mitosis process (1-4). Notably, dysregulated expression of SKA1/2/3 was involved in the tumorigenesis and progression of multiple cancer types such as liver cancer, breast cancer, cervical cancer and other malignant tumors (5-7), which in turn can affect the prognosis of cancer patients. High SKA1 expression contributed to the development and progression of hepatocellular carcinoma and reflected unfavorable prognosis (3). In breast cancer (BC), SKA2 is highly expressed and serves as a useful biomarker in both tumor initiation and progression (4). In addition, a high level of SKA3 was closely related to the cellular growth, proliferation, invasion and metastasis of cervical cancer cells and thus linked to poor prognosis (5). To date, however, most studies on SKA1/2/3 in cancers are based on a single tumor or single gene. The potential value for the clinical application of SKA1/2/3, especially in the area of prognosis and the functional role of pan-cancer, remains to be explored.

Around or inside the malignant tumor, stromal cells, endothelial cells, intrinsic cells, lymphocytes and their secreted active mediators exist, which can interact with malignant tumor cells, together forming a unique tumor microenvironment (TME) (8). There is a growing body of studies supporting the important role of the TME in tumorigenesis, tumor progression, and treatment efficacy (9, 10). Other studies have shown that immune cell infiltration in the TME is associated with the immunotherapy response (11). For instance, tumor-associated macrophages (TAMs) can serve as a cancer promoter and reflect an adverse prognosis for cancers by secreting molecules stimulating tumor growth (12, 13). In contrast, CD8+ and CD4+ T cells in the TME exert antitumor effects by recognizing and clearing dysplastic cancer cells, which are highly related to survival outcomes and immunotherapeutic responses in cancer patients (14). In addition, immune checkpoint inhibitors (ICIs) have recently been shown to be a promising therapy method in advanced cancer patients (15-17). Inhibition of immune checkpoint targets, including PD-1/PD-L1, is clinically effective in a variety of cancers (18). However, ICI therapy only benefits a small portion of cancer patients due to its low response rates. Therefore, the identification of reliable biomarkers for screening immunotherapy candidates and therapeutic targets in cancers is challenging and promising.

In this study, we conducted a comprehensive analysis of SKA1/ 2/3 at the pan-cancer level, including gene alterations (mutation, copy number, methylation), expression, prognostic value, pathway enrichment, effects on the tumor microenvironment (TME) and immunotherapy. We further established a scoring system (termed the SKA score) across cancers to provide more accurate prognostic information for individual patients. Our study specifically focuses on the possible impact of the SKA score in cancer and sheds new light on the biological roles of the SKA complex and the potential of the SKA score as a therapeutic response indicator and target for anticancer treatment.

Materials and methods

Data collection

Public data, including the RNA-seq matrix and corresponding clinical information of The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx), were downloaded from the UCSC Xena website (https://xenabrowser.net/datapages/) (19). Immune infiltration data were collected from the Immune Cell Abundance Identifier (ImmuCellAI) (20) (http:// bioinfo.life.hust.edu.cn/ImmuCellAI#!/) and TIMER2 databases (21) (http://timer.cistrome.org/) and matched with the clinical information downloaded from the UCSC Xena. The immunotherapy-related independent datasets GSE91061 and IMvigor210 were obtained from the Gene Expression Omnibus

Abbreviations: TCGA, The cancer genome atlas; GEO, Gene Expression Omnibus; GDSC, Genomics of Drug Sensitivity in Cancer; GSVA, Gene set variation analysis; GSEA, Gene set enrichment analysis; ssGSEA, single sample gene set enrichment analysis; TME, Tumor microenvironment; SNV, Single Nucleotide Variation; CNV, Copy number variation; PPI, Protein-protein interaction; ROC, receiver operating characteristic; TNF, Tumor necrosis; NFkB, Nuclear factor kappa B; EMT, Epithelial-mesenchymal transition; HR, Hazard ratio; CI, Confidence interval; OS, Overall survival; DSS, Disease specific survival; PFI, Progression free interval; DFI, Disease-free interval; Tem, Effective memory T cell; Th1, T helper cell 1; Th17, T helper cell 17; Th2, T helper cell 2; Treg, Regulatory T cells; TMB, Tumor mutation burden; MSI, microsatellite instability; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; HR, Hazard ratios.

(GEO) database (https://www.ncbi.nlm.nih.gov) and the website based on the Creative Commons 3.0 license (http://research-pub.Gene.com/imvigor210corebiologies).

Differentially expressed gene analysis

First, we investigated the expression heterogeneity of SKA family-related genes between tumor and nontumor tissues in 31 types of cancers by the "limma" package (22). The obtained results are displayed in a heatmap, with $P \ge 0.05$ set as white, red for high expression, blue for low expression, and numerical values representing logFC values. A functional protein association network was constructed for SKA1/2/3 using the STRING tool with high confidence (23).

Somatic copy number alteration and mutation analysis

To investigate the correlation between the mRNA expression and genomic alterations of the SKA family, we performed Spearman's rank correlation analysis based on the Gene Set Cancer Analysis (GSCA) database (24) (http://bioinfo.life.hust.edu.cn/GSCA/#/). GSCA is an integrated database analysis platform that supports the visualization of genomic and immunogenomic gene set cancer analysis. Data including single nucleotide variation (SNV), amplification, homozygous and heterozygous deletion and amplification were adopted for the assessment and analysis of the gene mutation status of SKA family genes. Spearman's correlation analysis was performed to determine the strength of associations.

DNA methylation analysis

By mining the UCSC database, we obtained DNA methylation (Illumina Human Methylation 450) data from 33 different types of tumors for further analyses. For some tumors, Infinium Human Methylation 450 data were lacking. Differential methylation of 13 pairs of cancerous tissues and normal tissues was analyzed by the Wilcoxon rank test. Genes with a P-value < 0.05 and logFC < 0 were regarded as hypomethylated, and those with a P-value < 0.05 and logFC > 0 were regarded as hypermethylated. Spearman's correlation analysis was performed to determine the strength of the association between methylation and gene expression levels. P < 0.05 was considered significant. All results were generated from the GSCA online database and presented as dot plots.

Establishment of the SKA score

To assess the prognostic value of the SKA family, the R (version 4.1.1) "GSVA" package was used to perform single-sample gene set enrichment analysis (ssGSEA) (25) to calculate the SKA score of each sample across 33 cancer types. The following is the basic principle of the specific SKA score generation: ssGSEA is a function

in the R package "GSVA". For the pan-cancer gene expression matrix, ssGSEA first sorted the expression levels of all genes in the sample to obtain its rank among all genes. Then, for the input SKA family gene set (includes SKA1, SKA2 and SKA3), the genes present in the expression data are found from the gene set and counted, and the expression levels of these genes are summed. Then, based on the abovementioned evaluation, the enrichment score of each gene in the pathway was calculated, and the gene sequence was further disrupted to recalculate the enrichment score, which was repeated 1000 times. Finally, the enrichment score was generated according to the empirical cumulative distribution function (ECDF), that is, the SKA score. Each sample in pan-cancer has an SKA score value. The corresponding R code is provided in the Supplementary Material (Table S1).

Prognostic analysis of SKA score

To analyze the effect of the SKA score on the survival outcomes of patients, such as overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI), we performed univariate Cox regression (UniCox) analyses across 33 cancer types based on the R "survminer" and "survival" packages. We performed Cox proportional hazards regression analyses and determined the hazard ratio (HR) with 95% confidence intervals and corresponding P-values to estimate the prognostic value of the SKA score in each cancer. The results were represented by a heatmap using the R "ggplot2" package. The Kaplan–Meier (KM) method was used to investigate the prognostic value of the SKA score in human cancers using the R packages limma, survival, and survminer. P < 0.05 was considered significant.

Gene enrichment analysis

To investigate the biological functions of SKA1/2/3 and its role in 33 cancer types, the R "GSVA" package (26) was used to perform gene set variation analysis (GSVA) enrichment analysis to assess the association between the SKA score and 50 HALLMARK pathways in 33 cancer types according to the MSigDB database (27) (http:// software.broadinstitute.org/gsea/msigdb/index.jsp).

Tumor microenvironment analysis

The TME score, including stromal score, immune score, ESTIMATE score, and tumor purity score, was computed for each patient in 33 cancer types using the R "ESTIMATE" package. In subsequent analysis, we further explored the correlation between the SKA score and these scores. For further validation, we obtained TME-related pathways from a previous study (28), which have been widely used in omics data analysis, and then calculated corresponding pathway scores to explore the correlation of the SKA score with immune cell infiltration at the pan-cancer level. The obtained results were displayed using a heatmap with the help of the R "ggplot2" package.

To assess the correlations between the SKA family genes and small-molecule drugs, we computed the Pearson correlation coefficients between SKA1/2/3 and the drug sensitivity percentage using the Genomics of Drug Sensitivity in Cancer (GDSC-https:// www.sanger.ac.uk/tool/gdsc-genomics-drug-sensitivity-cancer/) (29) and Cancer Therapeutics Response Portal (CTRP-https:// portals.broadinstitute.org/ctrp/) datasets.

Immunohistochemistry

We obtained five breast cancer (BC) or five gastric cancer (GC) and five paracancerous samples from The First Affiliated Hospital of Guangxi Medical University for immunohistochemistry. All patients were diagnosed as BC or GC by pathology. Clinicopathological data, such as sex and age, were collected. The study was conducted in accordance with the Declaration of Helsinki. This study was approved by ethics committee of the First Affiliated Hospital of Guangxi Medical University, Nanning, People's Republic of China. Anti-SKA1/2/3 antibody were purchased from Abcam website (Cambridge, MA). Immunohistochemical staining method followed the instructions of manufacturers. Ten visual fields(Scale bar=200 μ m) were randomly selected, and two researchers independently read the images. Hematoxylin stained the cell nucleus blue, and positive expression of diaminobenzidine (DAB) is brownish yellow.

Statistical analysis

All data are expressed as the mean \pm standard deviation (SD) unless indicated otherwise. Student's t-test or analysis of variance (ANOVA) was used to determine the differences among groups. For patients with the same ID, those ending in -01 are tumor tissues, and those ending in -11 are paired normal tissues. The method used is the paired t-test. The R software package (version 4.1.1, https://www.r-project.org/) was used for the statistical analysis. All correlations were performed with Pearson's correlation r, unless otherwise stated, and the results are mainly displayed in the heatmaps. The differences were considered statistically significant when P < 0.05 and were reported as follows: ****P < 0.0001, ***P < 0.001, **P < 0.05.

Results

mRNA level and prognostic value of the SKA family

First, based on the TCGA and GTEx databases, for each SKA family gene, we explored the differential expression across 33 cancer types. Table S2 lists the 33 cancer types, their abbreviations and sample size for each cancer type. Because normal tissue for UVM

and MESO was absent in TCGA and GTEx, these two cancer types for which differential analysis was not performed are not shown in the heatmap. The expression of 3 SKA family genes differed among 31 cancer types, as shown in Figure 1A. From this figure, we know that the SKA genes were highly expressed in the 30 cancer types, except for LAML. We speculate that SKA gene expression in LAML in this cancer type is quite different from that in other tumor types, which may be due to its hematological disease. Further analysis of TCGA pan-cancer data revealed a correlation between SKA family genes (Figure 1B). In Figure 1C, we preliminarily predicted the protein interactions of SKA1/2/3 through the String website. After reviewing the related literatures, we had learned some of the functions of these genes related to SKA family genes in cancer. CENPF could promote the progression of papillary thyroid carcinoma by affecting cell proliferation and apoptosis and the high expression (30) of CENPF was associated with the poor prognosis of breast cancer and bone metastasis (31). Kodama et al. found that SPDL1 can be regulated by MRTFB to inhibit the development of colorectal cancer (32). Zeng et al. found that the expression level of NDC80 in human glioblastoma cells was significantly higher than that in normal cells and that NDC80 could promote the proliferation and invasion of human glioblastoma cells (33). Qin et al. also found that BUB1B is highly expressed in nasopharyngeal carcinoma and that BUB1B can promote tumor progression by regulating the cell cycle (34). Zhu et al. found that BUB1 promoted the proliferation of liver cancer cells by activating the phosphorylation of SMAD2 (35). The above results shown that these genes also played potential roles in some types of cancer and the specific pathways or functions involved in these genes deserved further exploration in the future. In addition, we conducted a univariate analysis of each SKA family gene in 33 tumors (Figure 2A). Three genes in the SKA family were shown to be risk factors in tumors, including ACC, KICH, PCPG, MESO, KIRP, LGG, and LUAD. Kaplan-Meier curve analyses showed that the overexpression of SKA family genes in multiple cancer types, such as ACC, KICH, LGG, and LUAD, was related to a poor prognosis (Figure 2B).

Gene alterations of the SKA family

To explore the mutation status of SKA family genes in various cancer types, we investigated the SNV profile using GSCALite (24). SKA3 was identified as a deleterious mutated gene with the highest frequency in UCEC according to the heatmap of SNV percentage (Figure 3A). We next assessed the copy number variants (CNVs) of SKA1/2/3 across cancers. The distribution proportion for the different CNV types, including heterozygous amplification, heterozygous deletion, homozygous amplification, and homozygous deletion, was computed with each SKA family gene across 33 cancer types (Figure 3B). The landscape of CNVs of the three SKA family genes is heterozygous amplification and heterozygous deletion. Figure 3C shows a positive relationship between the CNV of SKA2 and its mRNA value in 22 of 33 cancer types. The mRNA level of SKA family genes was positively



FIGURE 1

mRNA expression of SKA1/2/3 across cancers. (A) Heatmap depicting the differential expression information (including Log fold-change and P value) of SKA1/2/3 at the pan-cancer level. (B) The Spearman correlation between SKA1, SKA2, and SKA3 is shown in the heatmap. The darker is the red color, the stronger is the correlation between genes. (C) The protein–protein interaction (PPI) networks among SKA1/2/3 proteins.



related to the CNV of homozygous or heterozygous amplification but negatively related to the CNV of homozygous or heterozygous deletion (Figures 3D, E). Furthermore, Figure 4A shows the methylation landscape of SKA1/2/3 in 33 cancer types. We found that the methylation levels of SKA1/2/3 differed among 13 cancer types (Figure 4A). Studies have generally confirmed that the DNA methylation level of genes is negatively correlated with the mRNA expression of genes (36, 37). A general negative correlation was observed between the methylation levels of SKA1/2/3 and their mRNA levels (Figure 4B). Our results also confirmed this phenomenon.

Survival analysis according to the SKA score

Considering the individual heterogeneity and complexity of SKA family genes, based on ssGSEA, we constructed a scoring system to quantify the SKA gene modification pattern of individual patients in each cancer type in the TCGA cohort, termed the SKA score. As shown in Figure 5A, TGCT had the highest SKA score, while KICH had the lowest SKA score. In addition, the SKA score was found to be elevated in cancer tissues, including BLCA, BRCA, CESC, CHOL, COAD, ESCA, HNSC, KIRC, KIRP, LIHC, LUAD,



Gene alterations in SKA1/2/3 across 33 cancer types. (A) The frequency landscape of deleterious mutations in 33 tumor types. (B) The CNV information of SKA1/2/3 in pan-cancer is summarized in the pie chart. (C) The relationship of CNV with the mRNA levels of SKA1/2/3. (D, E) The percentage of homozygous (D) or heterozygous (E) CNV (including homozygous amplification, homozygous deletion, heterozygous amplification, and heterozygous deletion) for each SKA member in pan-cancer.

LUSC, PCPG, PRAD, READ, STAD, THCA, and UCEC, compared with the cancer adjacent tissues (Figure 5B).

With univariate Cox regression, we investigated the prognostic value of the SKA score by analyzing the association of the SKA score with the four survival outcomes OS, DSS, DFI and PFI. For the univariate results in pan-cancer: (1) For OS, SKA score was a significant risk factor in KIRP (HR=13.232), LGG (HR=7.961), KIRC (HR=7.452), ACC (HR=11.988), KICH (HR=13.632), MESO (HR=8.638), PCPG (HR=32.607), LUAD (HR=2.457), PRAD (HR=12.535), PAAD (HR=4.311), SKCM (HR=2.374) and SARC (HR=2.361), whereas a protective factor in THYM (HR=-6.703) and LUSC (HR=-1.441) (Figure 6A); (2) For DSS, SKA score was a significant risk factor in KIRP (HR=19.602), KIRC (HR=11.133), LGG (HR=8.016), ACC (HR=40.122), LIHC (HR=5.216), LUAD

(HR=3.854), PRAD (HR=18.491), PAAD (HR=5.176), SKCM (HR=2.730) and BRCA (HR=-2.378) (Figure 6B); (3) For DFI, SKA score was a risk factor in KIRP (HR=18.135), THCA (HR=19.885), LIHC (HR=3.018), SARC (HR=3.601), BRCA (HR=2.347) (Figure 6C). The sample size with DFI information in Figure 6C was smaller and therefore had fewer positive results; (4) For PFI, SKA score was a significant risk factor in KIRP (HR=15.805), KIRC (HR=8.527), ACC (HR=11.401), LGG (HR=4.932), KICH (HR=15.216), MESO (HR=7.802), PRAD (HR=6.752), LIHC (HR=3.014), PAAD (HR=5.138), PCPG (HR=17.625), THCA (HR=10.452), SARC (HR=2.486), LUAD (HR=9.278) (Figure 6D). From these figures, we know that in terms of prognosis, the SKA score can be used as a potential prognostic risk factor in 11 cancer types, including KIRP, LGG, KIRC, ACC,



KICH, MESO, PCPG, LUAD, PRAD, PAAD, and SKCM. Taken together, these findings revealed that the SKA score was a robust risk factor for numerous cancer types and displayed a strong HR value at the pan-cancer level.

GSVA of SKA score

We conducted a GSVA to investigate the potential pathways likely affected by the SKA score according to 50 HALLMARK pathways. Figure 7 shows the correlation of the SKA score with the GSVA pathways. The obtained results showed that the SKA score was positively correlated with cell proliferation-related pathways and DNA replication in pan-cancer, such as E2F targets, G2M checkpoint, MYC targets V1/V2, mitotic spindle and DNA repair, which suggested that tumor cells might have a strong proliferation ability through those signaling pathways. To better explore the pathways SKA family genes may participate in, we also conducted GSEA using R package "clusterprofiler." We observed that SKA family genes were mainly enriched in cell cycle related pathways in most tumor types, including ACC, GBM, LGG, LIHC, LUSC, and UVM (Figures S1A–P). In the tumor microenvironment, these pathways are involved in tumorigenesis by mediating proliferation, migration, invasion, and metastasis. Additionally, the obtained results indicated that the SKA score was negatively related to immune-related pathways, such as the TGF beta signaling pathway, IL6-JAK-STAT3 signaling pathway and p53 pathway. Therefore, we speculate that patients in the high SKA score group may exert weaker tumor immunity, which may be one of the reasons for the poor prognosis of this group of patients.

Relationship between SKA score and the TME

We further explored the relationship between the SKA score and TME score (including stromal, immune and ESTIMATE scores) in 33 cancer types. We found that in most cancer types, the SKA score was negatively related to the stromal score, immune score, and ESTIMATE score but was positively associated with tumor purity



(Figure 8A). In the TME, the SKA score may suppress antitumor immunity and promote tumor cell proliferation, survival, and invasion. Next, we extracted and computed TME-related pathway scores from a published paper (28). Then, we explored the relationship between the SKA score and TME-related pathways. We also found that the SKA score was closely positively correlated with DNA replication, mismatch repair and DNA damage response but negatively correlated with immune and stromal-related pathways, including EMT1/2/3, CD8T effector, and immune checkpoint, in 33 cancer types (Figure 8B). Both analyses were similar.

Immune infiltrating analysis

The abovementioned results revealed that the SKA score was closely associated with the immune score. Thus, we further

investigated the relationship between the SKA score and immune cells in the TME. The obtained results revealed that the SKA score was negatively associated with most immune cells across cancers according to the TIMER2 database, indicating an immune-suppressive TME (Figure 9A). The results from the ImmuCellAI database revealed that the SKA score was also generally connected to immune cell infiltration in the TME at the pan-cancer level (Figure 9B). The results of the two analyses are consistent and mutually verifiable.

The correlation of SKA score with immunotherapy response

Immunotherapies targeting PD-1/PD-L1 have made great clinical progress in immune checkpoint therapy (38–40). Elevated

A B D DS DS DS DS 100 0.001 1323248-1439 0 </th <th>•</th> <th></th> <th></th> <th></th> <th>в</th> <th></th> <th></th> <th></th>	•				в			
Index Problem Heard refin Problem Problem Heard refin Index 0.001 1.3827(148-11-648) Problem Heard refin ACC 0.001 1.802(148-11-648) Index 0.001 1.3827(148-11-648) Problem Heard refin ACC 0.001 1.802(148-11-648) Index 0.001 1.802(148-11-648) Problem Heard refin Heard	А			05	D			DSS.
Supple share i province i		pvalue	Hazard ratio			pvalue	Hazard ratio	555
NICC	LGG	< 0.001	7.961(5.439-10.484)		KIRP	< 0.001	19.602(15.022-24.182)	
ACC -0001 11587(246-1637) MED -0001 1587(146-107)	KIRP	<0.001	7.452(8.969-17.495)		LGG	<0.001	11.133(8.102-14.165)	1
REC:0 10.001 13.027/2582112329 PERC:0 0.001 13.027/2582112329 PERC:0 0.001 13.027/2582112329 PERC:0 0.001 13.027/258211239 PERC:0 0.001 13.027/25821140 PERC:0 0.001 13.027/2582140 PERC:0 0.001 13.027/2582140 PERC:0 0.001 13.027/2	ACC	<0.001	11.988(7.460-16.515)		ACC	<0.001	11 790/7 161-16 420	11
NESD -0001 8288(4891-2228) PADD 0001 4311(144-800) 2330(1464-280) SIGC 0001 4311(144-800) 2330(1464-280) SIGC 0001 4311(144-800) 2330(1464-280) SIGC 0001 4311(144-800) SIGC 0001 5312(1431-680) SIGC 0001 5312(14	KICH	<0.001	13.632(7.968-19.297)		KICH	< 0.001	17.679(10.169-25.189)	
C PCPC 0-001 4-317(1434-1480) - 4-317(1434-1480	MESO	<0.001	8.638(4.951-12.326)	-	MESO	<0.001	9.933(5.417-14.449)	-
PADD 0000 1247(11987-1380) 1247(11987-1380) 1247(1247-141-047) 1248(1247-141-047) 1247(1247-141-047) 124	PCPG	<0.001	32.607(16.144-49.070)		PCPG	<0.001	40.122(19.931-60.312)	
FADD 0000 1314(1423-326) 1431(142-337-326) 000 1344(1423-326) 141	LUAD	< 0.001	2.457(1.056-3.858)		LIHC	<0.001	5.216(2.483-7.949)	-
SYCU 0001 237400475-4280 USC 0002 -5704(-1281-028) USC 0002 -5844(-1281-028) USC 0002 -5947(-1281-028) USC 0002 -1184(-1281-028) USC 0002 -1184(-1281-028) USC 0002 <	PRAD	0.009	12.535(3.108-21.962)		LUAD	<0.001	3.854(1.822-5.886)	-
1150 0.020 -4.70(-1281-0.795) 0200 0.030 -1.41(-271-0.007) 0200 000 1.238(0.114-0.007) 0200 0.030 -1.41(-230-0.087) 0200 0.030 -1.41(-230-0.087) 0200 0.031 -1.232(-230-0.087) 0200 0.031 -1.232(-230-0.087) 0200 0.031 -1.232(-230-0.087) 0200 0.031 -1.232(-230-0.087) 0200 0.031 -2.832(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.031 -2.842(-1.40-0.47) 0200 0.0314(-0.42) <	SKCM	0.015	2.374(0.453-4.295)		PRAD	0.003	18.491(6.266-30.716)	
SNRC 0.039 -1.441+2/37-0001 SNRC 0.039 2.38(1)114-6.091 DLC 0.039 2.38(1)114-6.091 SNRC 0.031 2.39(1)114-6.091 SNRC 0.031 2.39(1)114-6.091 SNRC 0.031 2.39(1)114-6.091 SNRC 0.031 2.39(1)114-6.091 SNRC 0.398 -0.29(1)114-6.011 SNRC 0.398 -0.29(1)114-6.011 SNRC 0.398 -0.017(1)23-83-2.001 UVM 0.398 -0.017(1)23-83-2.001 -0.011(1)23-110-100 <	THYM	0.026	-6.703(-12.6110.795)		PAAD	0.004	5.176(1.606-8.746)	
SARC 0.039 -12.31(0.114-0.80) DBC 0.060 -12.41(-2.28-2.32) DC 0.000 -12.41(-2.28-2.32) DC 0.010 -12.27(-2.38-2.38) CV 0.113 -1.220(-2.774-3.776) US 0.012 -221(+2.714-3.776) US 0.012 -123(+2.714-3.776) US 0.012 -123(+2.714-3.716) US 0.000 -133(+2.714-3.726) US 0.000 -1	LUSC	0.036	-1.441(-2.7910.091)	•	BRCA	0.009	2.730(0.670-4.790)	
DLBC 0.089 -12.319-26.078-0.441) LIBC 0.089 -2.211(-6.03-0.460) STAD 0.131 -1.21(-2.22-0.31) THCA 0.031 2.031(-120-276) BECA 0.039 2.031(-120-276) BECA 0.039 2.031(-120-276) UVM 0.539 2.031(-120-276) BECA 0.639 -0.031(-230-2.037) UVM 0.539 2.037(-100-2.76) BECA 0.539 -0.031(-230-2.037) UVM 0.539 3.038(-6.466-1.278) UVM 0.539 -0.031(-2.307-2.087) UVM 0.539 -0.031(-2.307-2.087) UVS 0.382 -0.074(-2.38-2.680) UVS 0.332 -6.41(-0.22-	SARC	0.039	2.361(0.114-4.609)	-	SARC	0.068	2.309(-0.171-4.789)	
LICG 0.100 1.481(-2.280-2.401) CO 0.117 -1.381(-4.119-0.491) UCEC 0.282 -2.381(-2.719-2.382) UCEC 0.282 -2.381(-2.719-2.382) UCEC 0.282 -2.381(-2.719-2.382) UCEC 0.531 -1.49(-4.219-2.282) UCEC 0.531 -1.49(-4.219-2.282) UCEC 0.531 -1.581(-4.119-4.292) UCEC 0.531 -1.49(-4.219-2.282) UCEC 0.531 -1.49(-4.219-2.282) UCEC 0.531 -1.49(-4.219-2.282) UCEC 0.531 -1.49(-4.219-2.282) UCEC 0.532 -1.531(-512-282) UCEC 0.532 -1.531(-512-282) UCEC 0.532 -0.571 1.491(-522-242) UCEC 0.532 -0.571(-532-54.02) -1.756(-148-54-32) UCEC 0.532 -0.571(-532-54.02) -1.756(-148-52-282) UCEC 0.532 -0.571(-532-54.02) -1.756(-148-52-282) UCEC 0.532 -0.571(-1.592-58) -1.576(-148-52-282) UCEC 0.533 2.571(-1.592-58) <td>DLBC</td> <td>0.058</td> <td>-12.319(-25.078-0.441)</td> <td></td> <td>BLCA</td> <td>0.085</td> <td>2.075(-0.289-4.439)</td> <td>.</td>	DLBC	0.058	-12.319(-25.078-0.441)		BLCA	0.085	2.075(-0.289-4.439)	.
STAD 0.123 -1.2311-6303 -1.2311-6303 STAD 0.123 -1.2311-6276-43713 -1.2311-6276-43713 UCEC 0.262 2.5331-610-64753 -1.2311-6276-43713 UCEC 0.262 2.5331-610-64753 -1.2311-6276-43713 UCEC 0.262 2.5331-610-64753 -1.2311-6276-6423 UCEC 0.632 1.5321-6280-5433 -1.2311-6276-6423 UCEC 0.632 1.5321-6280-5433 -1.2311-6276-6423 UCEC 0.632 1.5321-6280-5433 -1.2311-6276-5433 UCS 0.532 -1.2311-7132-64533 -1.2311-7132-64533 UCS 0.532 -0.0741-6333-6240 -0.0741-6337-6264 UCS 0.532 -0.0741-6337-62643 -0.0741-6337-62643 UCS </td <td>LIHC</td> <td>0.100</td> <td>1.461(-0.280-3.201)</td> <td>- <u>7</u></td> <td>ov</td> <td>0.117</td> <td>-1.361(-3.064-0.342)</td> <td>•</td>	LIHC	0.100	1.461(-0.280-3.201)	- <u>7</u>	ov	0.117	-1.361(-3.064-0.342)	•
STAD 0.113 0.114 0.123 - 1220 - 232 - 3283 0.012 0.026 0.028 - 2331 - 410 - 479 0.027 - 028 - 1230 - 410 - 2789 BECA 0.477 0.028 - 2381 - 410 - 2789 BECA 0.477 0.028 - 0.028 - 1382 - 1328 - 1329 0.028 - 0.028 - 1358 - 1329 - 12289 0.028 - 0.028 - 1358 - 1329 - 12287 0.028 - 0.028 - 2381 - 1370 - 1287 1.028 - 0.028 - 2381 - 1370 - 1287 1.028 - 0.028 - 2387 - 1388 - 1329 - 12287 1.028 - 0.027 - 1288 - 1389 - 12287 1.028 - 0.027 - 1288 -	COAD	0.108	-2 211(-5 063-0 640)	1	STAD	0.123	-1.814(-4.119-0.491)	
OV 0.134 -1.201(-2.77-0.3716) TUCCE 0.268 2.533(-1410-475) READ 0.313 -2.381(-140-475) READ 0.313 -2.381(-140-475) READ 0.588(-148-2113)	STAD	0.132	-1.270(-2.923-0.382)		HNSC	0.144	1.929(-0.659-4.516)	• •
TICA 0.187 -12.004/-27.98-3.789 -12.004/-27.98-3.789 UCEC 0.288 -2.5371-410-4.781 -10.004/-27.98-2.689 BLCA 0.477 0.6747-10-67-819 -10.004/-27.98-2.689 UCEC 0.533 -12.004/-27.98-2.689 -10.004/-27.98-2.289 UCEC 0.537 -11.084-1.589-3.589 -10.004/-27.98-2.289 UCEC 0.537 -11.084-1.589-3.589 -10.004/-27.98-2.289 UCEC 0.538 -12.007-7.38-2.289 -10.014/-2.39-3.289 UCS 0.597 -10.014/-2.398-3.589 -0.074/-6.39-3.281 UCS 0.928 -0.074/-6.39-3.281 -0.011 UCS 0.928 -0.031-01.194-5.199 -0.0131-07.23-04.127 UCS 0.928 -0.031-01.194-5.199 -0.011 UCS 0.928 -0.031-01.194-5.199 -0.011 UCS 0.928 -0.031-01.194-5.199 -0.011 UCS 0.928 -0.031-01.192-01.194-01.199 -0.031-01.192-01.194 UCS 0.928 -0.011 16.158/12.092/-01.192 -0.011 UCS 0.928 -0.011 16.158/12.092/-01.192 -0.0	ov	0.134	-1.201(-2.774-0.371)	+	DLBC	0.166	-11.948(-28.861-4.964)	
UCEC 0.280 2.535(-14)-6-759 + - <td>THCA</td> <td>0.136</td> <td>-12.004(-27.795-3.786)</td> <td></td> <td>READ</td> <td>0.167</td> <td>9.499(-3.981-22.978)</td> <td>1</td>	THCA	0.136	-12.004(-27.795-3.786)		READ	0.167	9.499(-3.981-22.978)	1
READ 0.313 -2.261(-8.710-2.788) BLCA 0.477 0.074(-1062-2410) CSS 0.477 0.474(-1062-2410) CSS 0.509 -0.639(-3.87-2.80) UCS 0.592 -0.274(-3.83-3.83) UCS 0.592 -0.274(-3.83-3.83) UCS 0.592 -0.274(-3.83-3.84) UCS 0.595 0.0770(-3.89-2.588) UCS 0.969 -0.131(-6.73-6.471) UCS 0.996 -0.131(-6.73-6.471) UCS 0.969 -0.1142(-74.97-22.737) HINGC 0.001 15.216(0.209-22.529) HISC 0.001 15.216(0.209-22.529) HISC 0.001 15.216(0.209-22.529) HISC 0.001 15.216(0.209-22.529) HISC 0.001 15.216(0.209-22.529) HISC 0.001 15.216(0.209-22.527) HISC 0.002 1.146(-3.159-3.500) HISC 0.002 1.146(-3.159-3.500) HISC 0.002 1.146(-3.159-3.500) HISC 0.002 1.146(-3.159-3.500)	UCEC	0.208	2.533(-1.410-6.475)	+	CESC	0.1/1	3.985(-1./26-9.696)	
LUA 0.474 0.0747 0.0847-2411) GPM 0.339 0.3384 -2648-1231 GPM 0.039 0.2084 -2647-2437 GPM 0.0524 1.359-1245 GPM 0.0552 1.135(-3725-085) LUSC 0.773 0.238(-3726-185) UCS 0.392 -0.074(-6.393-6.24) UCS 0.000 1 15.05(11.151-16.480-1.24) UCS 0.000 1 15.05(11.151-16.80) HERCA 0.044 12.678(-0.769-26.116) PADD 0.070 5.114(-6.271-6.23) UCS 0.393 -7.740(00-1.480-1.24) UCS 0.393 -7.740(00-24-1.480-1.24) UCS 0.393 -7.740(00-24-1.	READ	0.313	-2.961(-8.710-2.788)	-	CHO	0.247	-2.907(-7.994-2.059) 4 281(-3 347-11 909)	
C C C C C C C C C C C C C C	BLCA	0.447	0.674(-1.064-2.411)		THCA	0.338	-12.697(-38.692-13.298)	
C C C C C C C C C C C C C C	UVM GRM	0.539	-0.688/-3.186-1.811		UCEC	0.363	2.853(-3.294-8.999)	
C ESCA 0.352 1.336-1376-1381 UCS 0.395 0.070(-2.389-2.38)	CESC	0.631	1.149(-3.539-5.836)	<u> </u>	LUSC	0.371	1.418(-1.689-4.526)	+
LAMU 0.820 -0.294(-8.27-2.40) UCS 0.982 -0.074(-8.39-2.40) UCS 0.989 -0.01 18.135(12.242-24.027) THCA 0.0001 18.135(12.242-24.027) THCA 0.0001 18.135(12.242-24.027) THCA 0.0001 18.135(12.242-24.027) UCS 0.332 -0.612(-19.37-6.516) UCS 0.332 -0.612(-19.37-6.517) UCS 0.332 -0.612(-19.37-6.519) UCS 0.332 -0.612(-19.37-6.519) UCS 0.332 -0.612(-19.37-6.510) UCS 0.332 -0.613(-1.427-2.200) UCS 0.332 -0.613(-1.427-2.200) UCS 0.532 -0.613(-1.437-3.220) UCS 0.532 -0.613(-1.437-3.220) UCS 0.535 (-1.726(-1.437-3.200) UCS 0.535 (-1.726(-1.437-3.200) UCS 0.51(-5.131-2.203) UCS 0.51(-5.131-2.2	CHOL	0.652	1.135(-3.792-6.062)		ESCA	0.557	1.006(-2.351-4.363)	+
LANL 0.020 -0.284(-2827-2240) TGCT 0.879 -1.236(-7.126-14.539) UCS 0.995 0.070(-2.399-2.589) UCS 0.995 -0.074(-6.393-6.24) UCS 0.995 -0.074(-6.393-6.24) UCS 0.996 -0.13(-6.456)-1.42-31) UCS 0.332 -6.612(-19.974-6.750) PRAD 0.075 5.141(-0.521-10.803) UCS 0.332 -6.612(-19.974-6.750) PRAD 0.033 2.338(-3.437-10.270) UCS 0.338(-3.474-10.270) UCS 0.51(-5.157-5.180) UCS 0.51(-5.157-5.180) UCS 0.51(-5.157-5.180) UCS 0.51(-5.157-5.180) UCS 0.51(-5.157-5.180) UCS 0.51(-5.157-5.230) UCS 0.51(-5.157-5.180) UCS 0.51(-5.157-5.180)	HNSC	0.773	0.238(-1.376-1.851)	+	THYM	0.572	-2.507(-11.194-6.180)	-
TGCT 0.99 -1.235(-T1.72814.65) UCS 0.992 -0.074(-6.393-6.244) UCS 0.992 -0.074(-6.393-6.244) UCS 0.992 -0.074(-6.393-6.244) UCS 0.992 -0.074(-6.393-6.244) UCS 0.999 -0.131(-6.733-6.47) UCS 0.001 15.305(11.918-1.9692) UCS 0.011 12.618(8.208-2.22.25) PRAD 0.332 2.338(-4.32-10.509) ULRC 0.001 15.218(8.208-2.22.25) PCPG UAD 0.447 0.338(-4.427-0.569) 0.011 1.248(8.208-2.22.25) PCPG 0.011 1.248(8.208-2.22.25) PCPG UAD 0.338(-4.327-0.509) <	LAML	0.820	-0.294(-2.827-2.240)	+	UVM	0.584	2.791(-7.204-12.786)	
ESCA 0.955 0.070(-2.399-2.508) 0.070(-2.399-2.208) UCS 0.959 -0.13(-6.733-6.747) Participation 0C 0.959 -0.13(-6.733-6.747) C D 0C 0.959 -0.13(-6.733-6.747) RKRP 0.001 18.185(12.242-24.027) 0.959 -0.13(-6.733-6.747) THCA 0.001 18.185(12.242-24.027) 0.959 -0.13(-6.733-6.747) THCA 0.001 18.185(12.242-24.027) 0.959 -0.13(-6.733-6.747) RKRP 0.001 18.185(12.242-24.027) 0.959 -0.13(-6.733-6.747) RKRP 0.001 18.185(12.987-6.780) 0.951 -0.133(-6.712,-19.77) LUSC 0.332 -5.612(-19.374-6.780) 0.951 -5.72(-3.041-0.300) PRAD 0.3032 -5.612(-19.374-6.780) 0.951 -5.72(-3.041-0.300) PRAD 0.3032 -5.632(-3.041-0.337-6.780) 0.951 -5.632(-3.041-0.300) PRAD 0.3032 -5.632(-3.041-0.397-6.780) 0.951 -5.72(-3.041-0.300) PCFG 0.001 17.802(-8.58-6.83-8.40) 0.951 1.725(0.121-3.220)	TGCT	0.879	-1.235(-17.126-14.655)		GBM	0.747	-0.455(-3.222-2.313)	<u>.</u>
003 0.952 -0.014(-6.335-6.24) 0.951 -0.15(-6.135-6.21) 0.951 -0.15(-6.135-6.21) C DFI 0.952 0.951 15.805(11.916-19.62) 0.951 -0.15(-6.135-6.21) SARC 0.001 15.136(12.242-24.027) 0.953 15.805(11.916-19.62) 0.951 -0.15(-6.135-6.21) SARC 0.012 3.016(105-4.982) 0.951 -0.15(-6.135-6.21) 0.951 -0.15(-6.135-6.21) BRCA 0.044 2.347(0.060-4.634) 0.951 -0.15(-6.135-6.21) -0.15(-6.11-6.2)	ESCA	0.955	0.070(-2.369-2.508)		TGCT	0.836	-1.760(-18.450-14.931)	
OC D Pique Hazard ratio DF Value Hazard ratio Pique Hazard ratio DF NHCR + 0.001 18.155(12.242-24.027) D D Note that the stand ratio is the stand ratis the stand ratis the stand ratio is the stand ratio	003	0.982	-0.074(-0.393-0.244)	-28-20.5-13-6 -3 2 7 12 17 22 27 32 37 42 47	003	0.909	-0.131(-0.733-0.471)	-39 -29 -19 -0-41 6 111621263136414651566
pvalue Hazard ratio pvalue Hazard ratio pvalue Hazard ratio KIRP <0.001 18.135(12.42-40.027) + KIRP <0.001 18.05(11.918-10.62) LHC 0.003 3.018(1.055-4.982) LG ACC <0.001 18.058(12.918-7.056) BRCA 0.044 2.347(0.060-4.634) KICH MESO 0.064 12.678(-0.760-26.116) PRAD 7.802(3.799-11.805) + UUSC 0.133 2.742(-0.833-6.317) PAD Colo1 5.138(2.142-8.133) + UCS 0.332 3.398(-3.474-10.270) PCPG 0.001 5.138(2.142-8.133) + CHOL 0.401 3.603(-4.803-12.008) LINC A0.035 1.778(0.282-3.273) + LLG 0.447 0.874(-1.381-3.129) BLCA 0.035 1.738(0.148-4.120) + LUAD 0.447 0.874(-1.381-3.129) BRCA 0.045 2.134(0.148-4.120) + LUAD 0.447 0.874(-1.381-3.129) BRCA 0.055<								
KIRP <0.001	с			DEI	D			DEI
THCA <0.001	с	pvalue	Hazard ratio	DFI	D	pvalue	Hazard ratio	PFI
LINC 0.003 3.018(1.055-4.392) SARC 0.001 3.001(7.052-6.410) BRCA 0.044 2.347(0.060-4.634) MESO 0.064 12.678(-0.760-26.116) PAAD 0.075 5.144(-0.521-0.803) LUSC 0.133 2.742(-0.833-6.317) UCS 0.332 - 6.612(-19.974-6.750) PRAD 0.332 3.398(-3.474-10.270) CHOL 0.401 3.603(-4.803-12.008) LUAD 0.041 3.603(-4.803-12.008) LUAD 0.025 1.725(0.326-3.329) LUAD 0.447 0.874(-1.381-3.129) LUAD 0.447 0.874(-1.381-3.129) LUAD 0.447 0.874(-1.381-3.129) LUAD 0.447 0.874(-1.381-3.129) LUAD 0.447 0.511 - 2.603(-9.971-4.944) KICH 0.492 - 10.386(-40.017-19.245) CCAD 0.511 - 2.603(-9.971-4.944) KICH 0.492 - 10.386(-40.017-19.245) CCAD 0.511 - 2.603(-9.971-4.944) KICH 0.492 - 10.386(-40.017-19.245) CCAD 0.511 - 2.603(-9.971-4.944) STAD 0.512 - 1.759(-1.272-3.28) GESC 0.757 1.447(-6.53-5.188) CCAD 0.611 - 1.759(-3.212-0.841) BICA 0.051 1.738(-0.009-4.171) CCAD 0.611 - 1.759(-3.212-0.841) BICA 0.051 1.738(-0.009-4.171) CCAD 0.611 - 2.603(-9.971-4.944) STAD 0.512 - 0.913(-4.162-2.340) UCEC 0.113 3.528(-0.841-7.896) UCEC 0.113 3.528(-0.841-7.896) UCEC 0.113 3.528(-0.841-7.896) UCEC 0.114 3.523(-3.242-0.814) BICA 0.051 1.738(-0.07-3.471) CCSC 0.605 1.467(-7.482-1.286) GEM 0.185 - 1.699(-4.212-0.814) BICA 0.332 - 0.065-3.171 CCSC 0.650 1.145(-3.739-6.065) CCSC 0.650 1.145(-3.79-6.053) CCSC 0	C KIRP	pvalue <0.001	Hazard ratio 18.135(12.242–24.027)	DFI	D KIRP	pvalue	Hazard ratio 15.805(11.918–19.692) 9.527(5.905-11.246)	PFI
SARC 0.012 3.601(0.72-6.410) NICH -0.001 15.2168 206-22.226) BRCA 0.064 12.678(-0.760-26.116) PRAD 0.075 5.141(-0.521-10.803) LUSC 0.133 2.742(-0.833-6.317) PRAD 0.001 6.752(3.204-10.300) PRAD 0.332 -6.612(-19.974-6.750) PRAD 0.001 17.802(2.639-16.300) PRAD 0.332 3.398(-3.474-10.270) SARC 0.001 2.486(0.581-4.381) CHOL 0.401 0.803(-4.432-10.509) SKCM 0.002 1.776(0.282-3.273) LUAD 0.447 0.874(-1.381-3.122) BLCA 0.035 1.272(0.127-3.29) TGCT 0.447 0.874(-1.381-3.122) BLCA 0.035 1.272(0.127-3.29) CADD 0.511 -2.503(-9.971-4.964) HNSC 0.062 2.006(-0.09-4.10) KICH 0.492 -10.386(-40.017-19.245) BRCA 0.051 1.733(-0.006-3.471) KICH 0.492 -10.38(-40.971-4.964) HNSC 0.062 2.006(-0.09-4.10) - COAD 0.511 -2.503(-9.971-4.964) HNSC 0.062	C KIRP THCA	pvalue <0.001 <0.001	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855)	DFI	D KIRP KIRC	pvalue <0.001 <0.001	Hazard ratio 15.805(11.918–19.692) 8.527(5.808–11.246) 11.4017 (25–15 27)	PFI
BRCA 0.044 2.347(0.060-4.634) MESO <0.001	C KIRP THCA LIHC	pvalue <0.001 <0.001 0.003	Hazard ratio 18.135(12.242–24.027) 19.885(9.915–29.855) 3.018(1.055–4.982)	DFI	D KIRP KIRC ACC LGG	pvalue <0.001 <0.001 <0.001 <0.001	Hazard ratio 15.805(11.918–19.692) 8.527(5.808–11.246) 11.401(7.025–15.777) 4.932(2.808–7.052)	PFI
MESO 0.064 12.678(-0.760-26.116) PRAD <0.001	C KIRP THCA LIHC SARC	pvalue <0.001 <0.001 0.003 0.012	Hazard ratio 18.135(12.242–24.027) 19.885(9.915–29.855) 3.018(1.055–4.982) 3.601(0.792–6.410)	DFI	D KIRP KIRC ACC LGG KICH	pvalue <0.001 <0.001 <0.001 <0.001 <0.001	Hazard ratio 15.805(11.918-19.692) 8.527(5.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.225)	PFI
PAAD 0.075 5.141(-0.521-0.803) - LHC <0.001	C KIRP THCA LIHC SARC BRCA	pvalue <0.001 <0.001 0.003 0.012 0.044	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-28.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634)	DFI	D KIRP KIRC ACC LGG KICH MESO	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001	Hazard ratio 15.805(11.918–19.692) 8.527(5.808–11.246) 11.401(7.025–15.777) 4.932(2.808–7.056) 15.216(8.206–22.225) 7.802(3.799–11.805)	PFI
LUSC 0.133 2.742(-0.83-6.317) PCPG 0.001 5.138(2.143-6.133) UCS 0.332 -6.612(-19.97-6.750) PCPG 0.001 17.525(6.856-2.394) CHOL 0.401 3.603(-4.803-12.008) SRCM 0.025 1.725(0.827-3.23) LUAD 0.447 0.874(-1.381-3.129) BLCA 0.035 1.725(0.127-3.229) LUAD 0.447 0.874(-1.381-3.129) BLCA 0.035 1.725(0.127-3.229) LUAD 0.447 0.874(-1.381-3.129) BLCA 0.035 1.738(2.143-6.131) READ 0.552 -0.937(-4.964) CHOL 0.001 1.733(-0.005-3.171) CCSC 0.506 1.860(-4.826-8.546) CHOL 0.001 1.735(-0.007-3.471) CCSC 0.506 1.860(-4.826-8.546) CHOL 0.001 1.752(-3.127-3.28) CCSC 0.757 1.447(-6.917-3.85) CHOL 0.001 1.735(-0.007-3.471) CCSC 0.506 1.860(-4.826-8.546) CHOL 0.001 1.735(-0.007-3.471) CCSC 0.753 4.325(-2.622-3.1272) CHOL 0.001 1.752(-3.127-3.28) CCSC 0.757 1.447(-6.917-3.85) CHOL 0.001 1.735(-0.007-3.471) CCSC 0.606 2.675(-7.486-12.386) CHOL 0.005 1.735(-0.317-3.29) CCSC 0.753 4.325(-2.622-3.1272) CHOL 0.015 1.735(-0.317-3.220) CCSC 0.617 -0.689(-6.533-5.188) CHOL 0.016 1.756(-3.732-2.68) CCSC 0.630 1.145(-3.792-6.085) CHOL 0.116 1.562(-3.312-3.212-3.84) BLCA 0.834 0.491(-4.067-5.069) CCSC 0.650 1.145(-3.792-6.065) CCSC 0.650 0.551(-5.151-6.253) READ 0.976 -0.271(-17.646-17.105) READ 0.899 -0.402(-6.637-5.833) ULSC 0.897 -0.221(-2.222-2.042) CCSC 0.897 -0.221(-2.222-2.042) CCSC 0.897 -0.221(-2.622-3.222) CCSC 0.899 -0.402(-6.637-5.833) CCSC 0.897 -0.221(-2.622-3.222) CCSC 0.897 -0.221(-2.622-3.222) CCSC 0.899 -0.402(-6.637-5.833) CCSC 0.899 -0.402(-6.637-5.8	C KIRP THCA LIHC BRCA MESO	pvalue <0.001 <0.001 0.003 0.012 0.044 0.064	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-28.116)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001	Hazard ratio 15.805(11.918–19.602) 8.527(8.808–11.246) 11.401(7.025–15.777) 4.932(2.808–7.056) 15.216(6.206–22.225) 7.802(3.799–11.805) 6.752(3.204–10.300)	PFI
UCS 0.32 -6.612(-19.974-6.750) PCPG 0.001 17.529(6.856-28.394) PRAD 0.322 3.398(-3.474-10.270) SRC 0.009 10.452(6.391-6.384) LGG 0.425 3.038(-3.474-10.270) SRC 0.009 10.452(6.391-6.324) LGG 0.425 3.038(-4.402-10.509) SKCM 0.020 1.778(0.2823.273) LUAD 0.447 0.874(-1.381-3.129) BLCA 0.035 1.728(0.127-3.329) TGCT 0.447 1.981(-5.399-7.561) UVM 0.048 9.278(0.079-18.478) KICH 0.492 -10.386(-40.017-19.245) BRCA 0.061 1.733(-0.006-3.471) COAD 0.511 -2.503(-9.971-4.964) HNSC 0.062 2.006(-0.099-4.10) UCEC 0.586 1.860(-4.826-8.546) STAD 0.165 -1.528(-3.817-0.388) UCEC 0.586 1.860(-4.822-8.546) STAD 0.165 -1.528(-3.817-0.388) UCEC 0.586 1.860(-4.822-8.546) STAD 0.165 -1.698(-4.212-0.614) DLBC 0.694 5.381(-21.457-32.220) GBM 0.165 -1.698(-4.2	C KIRP THCA LIHC SARC BRCA MESO PAAD	pvalue <0.001 <0.001 0.003 0.012 0.044 0.064 0.075	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-28.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD LIHC	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001	Hazard ratio 15.805(11.918-19.692) 8.827(5.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.25) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.288-4.770)	PFI
PRAD 0.322 3.398(-3.474-10.270) IIICA 0.009 10.452(L39=15.0.49) CHOL 0.401 3.603(-4.803-12.008) LIAD 0.010 2.486(0.5913.81) LUGD 0.447 0.874(-1.381-3.129) SKCM 0.005 1.778(0.228-3.273) TGCT 0.447 1.881(-3.599-7.651) UVM 0.005 2.172(0.071-3.329) TGCT 0.447 1.981(-3.599-7.651) UVM 0.048 9.278(0.079-1.8178) KICH 0.492 -10.386(-40.017-19.245) BRCA 0.061 1.733(-0.006-3.471) STAD 0.552 -0.931(-4.166-2.340) UVM 0.048 9.278(0.079-1.8178) UCEC 0.586 1.860(-4.826-8.546) UCEC 0.116 -1.562(-3.517388) ACC 0.606 2.675(-7.486-12.836) GBM 0.116 -1.569(-4.212-0.814) DLBC 0.694 5.381(-2.147-3.2220) GBM 0.185 -1.699(-4.312-0.814) CESC 0.753 4.325(-2.622-3.1.272) THYM 0.166 -1.569(-4.212-0.814) PCPG 0.753 4.325(-2.623-3.1.272) THYM 0.516 -1.176(-4	C THCA LIHC BRCA MESO PAAD LUSC	pvalue <0.001 <0.003 0.012 0.044 0.064 0.075 0.133	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD LIHC PAAD	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001	Hazard ratio 15.805(11.918–19.692) 8.527(5.808–11.246) 11.401(7.025–15.777) 4.932(2.808–7.056) 15.216(8.206–22.225) 7.802(3.799–11.805) 6.752(3.204–10.300) 3.014(1.258–4.770) 5.138(2.143–8.133)	PFI
CHOL 0.401 3.603(-4.803-12.008) LGG 0.425 3.038(-4.432-10.509) LUAD 0.447 0.874(-1.381-3.129) TGCT 0.487 1.981(-3.599-7.681) COAD 0.511 -2.503(-9.971-4.964) STAD 0.582 -0.913(-4.162-2.340) UCEC 0.586 1.860(-4.822-6.8246) LUEC 0.586 1.860(-4.822-6.8246) CHOL 0.079 5.74(-6.757-12.166) UCEC 0.586 2.675(-7.486-12.386) CESC 0.737 1.447(-6.991-9.885) CCAD 0.511 -0.582(-2.202-12.72) CESC 0.737 1.447(-6.991-9.885) COAD 0.511 -0.582(-2.202-12.72) CESC 0.737 1.447(-6.991-9.885) CCAD 0.517 -0.689(-6.533-5.188) BLCA 0.834 0.491(-4.087-5.069) BLCA 0.834 0.491(-4.087-5.069) BLCA 0.834 0.491(-4.087-5.069) CCAD 0.976 -0.271(-17.646-17.183) BLCA 0.834 0.491(-4.087-5.069) CCAD 0.976 -0.271(-17.646-17.183) CCAD 0.976 -0.271(-17.646-17.183) CCAD 0.976 -0.271(-17.646-17.183) CCAD 0.997 -0.027(-2.19.2-0.202) CESC 0.977 0.0276 -0.271(-17.646-17.183) CCAD 0.997 -0.027(-2.19.2-0.02) CESC 0.976 -0.271(-17.646-17.183) CCAD 0.999 -0.402(-6.37-5.633) CCAD 0.999 -0.402(-6.37-5.633) CCAD 0.899 -0.402(-6.37-5	C KIRP THCA LIHC SARC BRCA MESO PAAD LUSC UCS	pvalue <0.001 <0.003 0.012 0.044 0.064 0.075 0.133 0.332	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.601(0.792-6.410) 2.347(0.660-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD LIHC PAAD PCPG	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001	Hazard ratio 15.805(11.918-19.602) 8.527(5.808-11.246) 11.401(7.025-15.777) 15.216(8.206-22.225) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.258-4.770) 5.138(2.143-8.133) 17.625(6.856-28.304) 10.452(9.250-49.275)	PFI
LGG 0.425 3.038(-4.432-10.509) LUAD 0.447 0.874(-1.381-3.129) TGCT 0.447 0.874(-1.381-3.129) TGCT 0.447 0.874(-1.381-3.129) COAD 0.511 -2.503(-9.971-4.964) VUW 0.489 2.278(0.791-8.148) COAD 0.511 -2.503(-9.971-4.964) UCEC 0.586 1.860(-4.826-8.546) ACC 0.566 2.576(-7.486-12.336) ACC 0.566 1.860(-4.826-8.546) CESC 0.737 1.447(-6.919-885) CESC 0.737 1.447(-6.919-885) CESC 0.737 1.447(-6.919-885) CESC 0.737 1.447(-6.919-885) CESC 0.737 1.447(-6.919-885) CESC 0.661 2.576(-7.4865-1.972) CESC 0.6617 -0.688(-5.33-5.188) BLCA 0.334 -4.007) CESC 0.650 0.551(-5.151-6.253) READ 0.976 -0.271(-17.646-17.105) BLCA 0.899 -0.402(-6.37-5.039) CESC 0.650 0.551(-5.151-6.253) READ 0.976 -0.271(-17.646-17.1813) CESC 0.976 -0.271(-17.646-17.1813) CESC 0.976 -0.271(-17.646-17.1813) CESC 0.976 -0.271(-17.646-17.1813) CESC 0.976 -0.271(-17.646-17.1813) CESC 0.997 -0.021(-2.622-0.024) CESC 0.680 0.551(-5.151-6.253) READ 0.996 -0.427(-1.7646-17.1813) CESC 0.899 -0.402(-6.37-5.833) CESC 0.971 -0.106(-5.454-5.833) CESC 0.971 -0.106(-5.454-5.83) CESC 0.971	C KIRP THCA LIHC SARC BRCA MESO PAAD LUSC UCS PRAD	pvalue <0.001 <0.001 0.003 0.012 0.044 0.064 0.075 0.133 0.332 0.332	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.398(-3.747-10.270)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD LIHC PAAD PCPG THCA SAPC	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001 0.001 0.009 0.019	Hazard ratio 15.805(11.918–19.692) 8.527(5.808–11.246) 11.401(7.025–15.777) 4.932(2.808–7.056) 15.216(8.206–22.25) 7.802(3.799–11.805) 6.752(3.204–10.300) 3.014(1.288–4.770) 5.138(2.143–8.133) 17.625(6.855–28.394) 10.452(2.639–18.264) 2.456(7.631–4.264)	PFI
LUAD 0.447 0.874(-1.381-3.129) TGCT 0.487 1.981(-3.599-7.561) V/M 0.048 9.278(0.079-18.473) KICH 0.492 -10.386(-4.0177-19.245) COAD 0.511 -2.503(-9.971-4.964) STAD 0.582 -0.931(-4.166-2.340) UCEC 0.586 1.860(-4.826-8.546) ACC 0.606 2.675(-7.486-12.386) CESC 0.737 1.447(-6.991-9.885) CESC 0.737 1.447(-6.991-9.885) CESC 0.737 1.447(-6.991-9.885) CESC 0.737 1.447(-6.991-9.885) CESC 0.737 1.447(-6.991-9.885) CCSC 0.753 4.325(-2.622-3.1272) V 0.788 0.315(-1.187-3.2220) HNSC 0.817 -0.689(-6.533-5.188) BLCA 0.035 1.135(-1.619(-4.212-0.814) CESC 0.817 -0.689(-6.833-5.188) BLCA 0.048 9.278(0.079-18.478) UCEC 0.131 3.528(-0.691-4.212-0.814) CESC 0.191 1.750(-0.872-4.212-0.814) CESC 0.850 1.145(-3.795-6.085) V 0.788 0.315(-1.983-2.612) CESC 0.850 1.145(-3.795-6.085) ULBC 0.681 1.250(-6.833-3.733) BLCA 0.834 0.491(-4.087-5.069) V 0 076 0.551(-5.151-6.253) READ 0.976 -0.271(-17.646-17.165) KIRC 0.976 -0.271(-17.646-17.181) V 0 0.066 0.971 -0.06(-5.834-5.633) ULSC 0.899 -0.402(-6.37-5.833) ULSC 0.891 -0.106(-5.844-5.831) ULSC 0.891 -0.106(-5.8	C KIRP THCA LIHC BRCA MESO PAAD LUSC UCS PRAD CHOL	pvalue <0.001 <0.001 0.003 0.012 0.044 0.064 0.075 0.133 0.332 0.332 0.332	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.603(-4.803-12.008)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD LIHC PAAD PCPG THCA SARC LIAP	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001 0.001 0.001 0.009	Hazard ratio 15.805(11.918–19.662) 8.527(8.808–11.246) 11.401(7.025–15.777) 4.932(2.808–7.056) 15.216(8.206–22.225) 7.802(3.799–11.805) 6.752(3.204–10.300) 3.014(1.258–4.770) 5.138(2.143–8.133) 17.625(6.856–28.394) 10.452(2.639–18.264) 2.486(0.591–4.381) 1.778(0.822–3.733)	PFI
TGCT 0.497 1.981(-3.599-7.561) UWN 0.048 9.278(0.079-18.478) KICH 0.492 -10.386(-40.017-19.245) BRCA 0.051 1.733(-0.006-3.471) STAD 0.582 -0.931(-4.166-2.340) HNSC 0.062 2.008(-0.099-4.10) UCEC 0.586 1.860(-4.826-8.546) UCEC 0.138 5.282(-0.841-7.396) DLBC 0.694 5.381(-21.457-32.220) GBM 0.185 -1.699(-4.212-3.08) CESC 0.737 1.447(-6.91-9.885) COAD 0.416 -1.562(-3.512-0.384) PCPG 0.738 0.315(-1.983-2.612) COAD 0.416 -1.659(-4.312-0.384) HNSC 0.817 -0.698(-5.933-5.198) COAD 0.407 -1.446(-4.4865-1.972) HNSC 0.817 -0.698(-6.593-5.198) DLBC 0.612 2.505(-6.863-1.312) HNSC 0.851 0.516(-1.514-6.233) DLBC 0.6854 1.032(-3.043-6.007) HNSC 0.976 -0.271(-17.64-17.105) KEAD 0.899 -0.402(-6.637-5.833) UCES HNSC 0.851(-5.154-6.233) ULSC 0.8971 -0.2	C KIRP THCA SARC BRCA MESO PAAD LUSC UCS PRAD CHOL LGG	pvalue <0.001 0.003 0.012 0.044 0.064 0.075 0.133 0.332 0.332 0.401 0.425	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.398(-3.474-10.270) 3.038(-4.432-10.508) 3.038(-4.432-10.508)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD LIHC PAAD PCPG SARC LUAD SKCM	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001 0.009 0.010 0.020 0.032	Hazard ratio 15.805(11.918-19.602) 8.527(5.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.25) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.258-4.770) 5.138(2.143-8.133) 17.625(6.856-28.394) 10.452(2.639-18.264) 2.436(6.051-4.381) 1.778(0.282-3.273) 1.725(0.511-3.329)	PFI
KICH 0.492 -10.386(-40.017-19.245) BRCA 0.051 1.733(-0.006-3.471) COAD 0.511 -2.503(-9.971-4.964) HNSC 0.062 2.006(-0.098-4.10) STAD 0.552 -0.913(-4.166-2.340) HNSC 0.062 3.208(-0.041-7.896) UCEC 0.566 1.860(-4.826-8.546) UCEC 0.116 -1.562(-3.512-3.08) ACC 0.664 5.381(-21.457-32.220) STAD D116 -1.569(-4.212-0.814) DLBC 0.694 5.381(-21.457-32.220) ESCA 0.191 1.706(-0.872-3.127-3.88) CESC 0.737 1.447(-6.91-9.885) CAD 0.191 1.706(-4.722-3.89) VO 0.783 4.325(-2.262-31.272) THYM O.191 1.716(-4.722-3.89) HNSC 0.817 -0.089(-6.53-5.198) OV 0.561 1.145(-3.796-6.085) BLCA 0.834 0.491(-4.047-5.069) OV 0.665 0.338(-1.191-1.868) BLCA 0.850 0.551(-5.151-6.253) ULSC 0.807 0.291(-2.622-0.02) KIRC 0.976 -0.271(-17.646-17.105) READ 0.899 -0.402(-6.6	C KIRP THCA LIHC SARC BRCA MESO PAAD LUSC UCS PRAD CHOL LUSC LUAD	pvalue <0.001 0.003 0.012 0.044 0.064 0.075 0.133 0.332 0.332 0.332 0.447	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.732-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.398(-4.472-10.208) 3.038(-4.432-10.089) 0.874(-1.381-3.129)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD LIHC PAAD PCPG THCA SARC LUAD SKCM BLCA	pvalue <0.001	Hazard ratio 15.805(11.918-19.692) 8.527(5.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.25) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.288-4.770) 5.138(2.143-8.133) 17.625(6.856-28.394) 10.452(2.639-18.264) 2.486(0.591-4.381) 1.775(0.282-3.273) 1.725(0.121-3.329) 2.134(0.148-4.120)	PFI
COAD 0.511 -2.503(-9.971-4.964)	C KIRP THCA LIHC SARC BRCA MESO PAAD LUSC PRAD CHOL LGG LUAD	pvalue <0.001 <0.003 0.012 0.044 0.064 0.075 0.133 0.332 0.332 0.401 0.425 0.447	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.660-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.308(-3.474-10.270) 3.603(-4.463-12.008) 3.038(-4.432-10.509) 0.874(-1.381-3.129) 1.881(-3.599-7.561)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD LIHC PAAD PCPG THCA SARC LUAD SKCM BLCA UVM	pvalue <0.001	Hazard ratio 15.805(11.918-19.602) 8.527(8.608-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216[8.206-22.225] 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.258-4.770) 5.138[2.143-8.133] 17.625(8.856-28.394) 10.452(2.639-18.264) 2.486(0.591-4.381) 1.776(0.282-3.273) 1.725(0.121-3.329) 2.134(0.148-4.120) 9.278(0.079-18.478)	PFI
STAD 0.582 -0.913(-4.166-2.340) CHCL 0.079 5.746(-0.675-12.166) UCEC 0.586 1.860(-4.826-8.546) STAD 0.113 3.226(-0.847-7.896) ACC 0.606 2.675(-7.486-12.836) STAD 0.116 -1.562(-3.512-0.388) DLBC 0.694 5.381(-21.457-32.220) STAD 0.116 -1.562(-3.512-0.388) CESC 0.737 1.447(-5.919-9.885) CAD CAD 0.417 -1.6486-1.972) OV 0.788 0.315(-1.983-2.612) CAD 0.407 -1.446(-4.4865-1.972) HNSC 0.817 -0.689(-5.833-5.198) CSC 0.661 1.56(-5.683-1.73) BLCA 0.830 0.551(-5.151-6.23) DLBC 0.662 0.338(-1.191-1.868) READ 0.976 -0.271(-17.646-17.105) TGCT 0.684 1.032(-3.043-6.007) BLCA 0.850 0.551(-5.151-6.233) UCS 0.971 -0.291(-2.622-0.42) CUSC 0.971 -0.066(-1.1945-1.18.13) CUSC 0.971 -0.106(-5.844-5.83) UCS 0.971 -0.016(-5.845-5.831) CUSC 0.971	C KIRP THCA LIHC SARC BRCA MESO PAAD LUSC UCS PRAD CHOL LGG LUAD TGCT KICH	pvalue <0.001 <0.003 0.012 0.044 0.064 0.053 0.133 0.332 0.332 0.401 0.425 0.447 0.487 0.487	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.398(-3.474-10.270) 3.033(-4.432-10.509) 0.874(-1.381-3.129) 1.9.81(-3.599-7.561) -10.386(-40.077-19.245)	DFI	D KIRP KICC LGG KICH MESO PRAD PCPG THCA SARC LUAD SACM BLCA UVM BRCA	pvalue <0.001	Hazard ratio 15.805(11.918-19.692) 8.527(5.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.25) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.258-4.770) 5.138(2.143-8.133) 17.625(6.856-28.394) 10.452(2.639-18.264) 2.486(6.051-4.381) 1.778(0.6281-3.273) 1.725(0.651-4.381) 1.725(0.651-4.381) 1.725(0.051-4.381) 1.725(0.051-4.381) 1.733(0.006-3.471)	PFI
UCEC 0.586 1.860(-4.826-8.546) UCEC 0.113 3.528(-0.841-7.896) ACC 0.606 2.675(-7.486-12.836) STAD 0.116 -1.569(-4.212-0.814) DLBC 0.694 5.381(-2.147-3.2220) STAD 0.116 -1.569(-4.212-0.814) CESC 0.737 1.447(-6.91-9.885) COAD 0.497 -1.469(-4.826-1.972) PCPG 0.753 4.325(-2.622-3.1272) CESC 0.561 -1.176(-4.722-2.369) V 0.788 0.315(-1.983-2.612) CESC 0.650 1.145(-3.795-6.085) HNSC 0.817 -0.689(-6.533-5.188) OV Ove 0.665 0.336(-1.191-1.869) BLCA 0.834 0.491(-4.047-5.069) OV Ove 0.665 0.358(-1.91-1.869) KIRC 0.991 -0.066(-11.945-11.813) ULSC 0.897 -0.402(-6.637-5.633) WCS 0.991 -0.066(-11.945-11.813) -0.402(-6.537-5.633) -0.402(-6.537-5.633)	C KIRP THCA LIHC BRCA MESO PRAD LUSC UCS PRAD CHOL LGG CHOL LGG LUAD TGCT KICH	pvalue <0.001 <0.003 0.012 0.044 0.064 0.075 0.133 0.332 0.332 0.401 0.425 0.447 0.487 0.492	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-28.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.038(-4.432-10.639) 3.038(-4.432-10.509) 3.038(-4.432-10.509) 1.981(-3.599-7.561) -10.386(-40.017-19.245) -2.503(-9.571-4.964)	DFI	D KIRP ACC LGG KICH MESO PRAD PCPG THCA SARC LLIAD SKCM BRCA HNSC	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001 0.001 0.000 0.010 0.020 0.035 0.035 0.048 0.062	Hazard ratio 15.805(11.918–19.602) 8.527(8.808–11.246) 11.401(7.025–15.777) 4.932(2.808–7.056) 15.216(8.206–22.225) 7.802(3.799–11.805) 6.752(3.204–10.300) 3.014(1.288–4.770) 5.138(2.143–8.133) 17.625(6.856–28.394) 10.452(2.639–18.248) 2.486(0.591–4.381) 1.776(0.282–3.273) 1.775(0.282–3.273) 1.775(0.282–3.273) 1.775(0.282–3.273) 1.733(-0.009–3.471) 2.306(-0.099–4.110) 1.206(-0.099–4.110)	PFI
ACC 0.606 2.675(-7.486-12.836) SIAD 0.116 -1.552(-3.512-0.388) DLBC 0.694 5.381(-21.457-32.220) GBM 0.115 -1.699(-4.212-0.384) CESC 0.737 1.447(-6.391-9.885) COAD COAD 0.407 -1.446(-4.865-1.972) PCPG 0.738 0.315(-1.932-2.612) COAD 0.407 -1.446(-4.865-1.972) WNSC 0.817 -0.698(-6.593-5.198) DLBC 0.661 2.505(-6.633-7.03) BLCA 0.834 0.491(-4.087-5.069) DLBC 0.681 2.305(-6.607) ESCA 0.976 -0.271(-17.646-17.105) TGCT 0.684 0.332(-3.432-6.007) READ 0.976 -0.271(-17.646-17.105) READ 0.897 -0.402(-6.637-5.833) UCS 0.971 -0.066(-11.945-11.813) -0.402(-6.637-5.633) 0.532(-5.437-5.633)	C KIRP THCA LINC SARC BRCA MESO PAAD LUSC UCS PRAD CHOL LGG LUAD TGCT KICH COAD	pvalue <0.001 0.003 0.012 0.044 0.075 0.133 0.332 0.332 0.401 0.425 0.447 0.492 0.512	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.001(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.038(-4.432-10.509) 0.874(-1.381-3.129) 1.987(-1.381-3.129) 1.984(-4.432-10.509) 0.874(-1.381-3.129) 1.984(-4.399-7.561) -10.386(-40.017-19.245) -2.603(-9.971-4.46-2.340) -0.913(-4.166-2.340)	DFI	D KIRP KICC LGG KICH MESO PRAD PCPG THCA SARC LUAD SKCM BLCA UVM W BRCA HNSC CHOL	pvalue <0.001	Hazard ratio 15.805(11.918-19.602) 8.527(5.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.25) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.258-4.770) 5.138(2.143-8.133) 17.625(6.856-28.394) 10.452(2.639-18.264) 2.436(0.651-4.381) 1.778(0.282-3.273) 1.725(0.651-4.381) 1.733(-0.061-3.471) 2.273(0.079-18.478) 1.733(-0.069-4.110) 5.746(-0.675-12.166)	PFI ++++++++++++++++++++++++++++++++++++
DLBC 0.694 5.381(-21.457-32.220) GEN 0.193 -1.099(-4.12-0.014) CESC 0.737 1.447(-6.91-9.885) ESCA 0.191 1.709(-8.72-4.270.014) OV 0.788 0.315(-1.983-2.612) CESC 0.661 2.505(-6.657-3.198) OV 0.788 0.315(-1.983-2.612) DLBC 0.661 2.505(-6.658-3.57.39) HNSC 0.817 -0.089(-6.539-5.198) OV 0.661 2.505(-6.658-3.57.3) BLCA 0.834 0.491(-4.067-5.069) OV 0.665 0.338(-1.191-1.1868) ESCA 0.850 0.551(-5.151-6.253) ULSC 0.807 0.291(-2.622-0.02) READ 0.991 -0.066(-11.945-11.813) UCS 0.971 -0.106(-5.844-5.633) UCS 0.971 -0.106(-5.844-5.633) -0.106(-5.844-5.633) -0.106(-5.844-5.633)	C KIRP THCA LIHC SARC BRCA MESO PAAD LUSC UCS PRAD CHOL LGG LUAD TGCT KICH COAD STAD	pvalue <0.001 0.003 0.012 0.044 0.075 0.133 0.332 0.332 0.401 0.425 0.447 0.487 0.487 0.487 0.492 0.511 0.582 0.582	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.732-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.038(-4.432-41.0209) 1.038(-4.432-41.0209) 1.981(-3.899-7.561) -10.386(-40.017-19.245) -2.503(-9.971-4.964) -0.913(-4.452-6.340) 1.860(-4.252-6.340)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD PAAD PCPG THCA SARC LUAD SKCM BLCA SKCM BLCA CHOL UVM	pvalue <0.001	Hazard ratio 15.805(11.918–19.692) 8.527(8.808–11.246) 11.401(7.025–15.777) 4.932(2.808–7.056) 15.216(8.206–22.225) 7.802(3.799–11.805) 6.752(3.204–10.300) 3.014(1.258–4.770) 5.138(2.143–8.133) 17.625(6.565–28.394) 10.452(2.639–18.264) 2.486(0.591–4.381) 1.778(0.028–3.273) 1.725(0.121–3.329) 2.134(0.148–4.120) 9.278(0.079–18.478) 1.733(-0.06–3.4711) 5.746(-0.06–3.47110) 5.746(-0.641–7.4866) 3.228(-0.441–7.4866)	PFI
CESC 0.737 1.447(-5.91-9.885) COAD 0.467(-4.865-1.92) PCPG 0.753 4.325(-22.622-31.272) THYM 0.516 -1.176(-4.722-2.369) OV 0.788 0.315(-1.983-2.612) THYM 0.516 -1.176(-4.722-2.369) HNSC 0.817 -0.689(-5.935-5.188) DLBC 0.661 2.505(-8.683-13.703) BLCA 0.834 0.491(-4.087-5.069) TGCT 0.684 1.032(-3.943-6.07) ESCA 0.850 0.551(-5.151-6.253) ULSC 0.807 -0.291(-2.624-2.042) READ 0.976 -0.271(-17.66-17.105) READ 0.899 -0.402(-6.637-5.633) USS 0.991 -0.066(-11.945-11.813) USS 0.971 -0.106(-5.844-5.631)	C KIRP THCA LIHC BRCA MESO PAAD LUSC PRAD UCS PRAD LUSC LIAG LUAD LGG LUAD TGCT KICH COAD STAD UCEC ACC	pvalue <0.001 <0.001 0.012 0.044 0.064 0.075 0.133 0.332 0.401 0.425 0.447 0.487 0.487 0.487 0.482 0.586 0.586	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.633-6.317) -6.612(-19.974-6.750) 3.398(-3.474-10.270) 3.603(-4.432-10.059) 0.874(-1.381-3.129) 1.981(-3.598-7.561) -2.503(-9.971-4.964) -0.931(-4.162-3.340) 1.860(-4.8226-5.546) 2.675(-7.466-2.340)	DFI	D KIRP KIRC LGG KICH MESO PRAD PAD PAD PAD SKCM BLCA UVM BRCA HNSC CHOL UCEC STAD	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.009 0.010 0.020 0.035 0.035 0.048 0.051 0.061 0.061 0.061 0.061 0.079 0.113 0.116	Hazard ratio 15.805(11.918-19.602) 8.527(8.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216[8.206-22.225] 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.258-4.770) 5.138(2.143-8.133) 17.625(8.856-28.394) 10.452(2.639-18.264) 2.486(0.591-4.381) 1.776(0.289-3.273) 2.134(0.148-4.120) 9.278(0.079-18.478) 1.733(-0.006-3.471) 2.006(-0.09-4.110) 5.362(-0.694-1.786) -1.552(-3.512-0.388) 4.2012 - 0.212	PFI
PCPG 0.753 4.226(-22.622-31.272) THYM 0.456 -1.776(-4.722-3.239) OV 0.788 0.315(-1.933-2.612) THYM 0.556 -1.176(-4.722-3.239) HNSC 0.8317 -0.698(-6.593-5.198) DLEC 0.661 2.505(-6.863-1.373) ESCA 0.834 0.491(-4.087-5.069) DLEC 0.684 1.032(-3.943-6.07) ESCA 0.850 0.571(-5.154-6.233) Lusc 0.807 0.291(-2.624-2.042) READ 0.976 -0.271(-17.646-17.105) Minimum distribution distributio	C KIRP THCA LIHC SARC BRCA MESO PAAD LUSC UCS PRAD CHOL LGG LUAD TGCT KICH COAD STAD UCEC ACC DI BC	pvalue <0.001 <0.001 0.042 0.044 0.064 0.075 0.133 0.332 0.401 0.425 0.447 0.487 0.482 0.511 0.586 0.586 0.696	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.082) 3.018(1.055-4.082) 3.018(1.055-4.082) 1.247(0.060-4.534) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.038(-4.432-10.098) 3.038(-4.432-10.098) 3.038(-4.432-10.599) 1.038(-4.040-17-19.245) -1.038(4-040-17-19.245) -2.503(-9.971-4.864) -0.913(-4.168-2.340) 1.860(-4.252-5.464) 2.675(-7.486-12.836) 5.581(-2147-32.290)	DFI	D KIRP KICC LGG KICH MESO PRAD PCPG THCA SARC LUAD SLCA UVM BRCA SLCA UVM BRCA SCC CHOL UCEC STAD GEM	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.009 0.010 0.035 0.045 0.045 0.051 0.062 0.079 0.113 0.116 0.185	Hazard ratio 15.805(11.918-19.602) 8.527(5.808-11.246) 11.401(7.028-15.777) 4.932(2.808-7.056) 15.216(8.206-22.25) 7.802(3.799-11.805) 6.752(3.024-10.300) 3.014(1.258-4.770) 5.138(2.143-8.133) 17.625(6.856-28.394) 10.452(2.639-18.264) 2.436(0.591-4.381) 1.778(0.6591-4.381) 1.778(0.0591-4.381) 1.778(0.0591-4.381) 1.725(0.0591-4.381) 1.735(0.006-3.4711) 2.006(-0.099-4.110) 5.746(-0.675-12.166) 3.522(-0.841-7.386) -1.569(-4.212-0.814) 1.552(-3.512-0.388)	PFI
OV 0.0100 1.0100 0.0102	C KIRP THCA LIHC SARC BRCA MESO PAAD LUSC UCS PRAD CHOL LGG CHOL LGG CHOL CAO STAD UCEC ACC DLBC CESC	pvalue <0.001 0.003 0.012 0.044 0.064 0.073 0.332 0.332 0.401 0.425 0.447 0.487 0.487 0.487 0.487 0.582 0.541 0.582 0.566 0.694 0.737	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-28.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.038(-4.432-10.639) 3.038(-4.432-10.509) 0.874(-1.381-3.129) 1.981(-3.599-7.561) -10.386(-4.017-19.245) -2.630(-9.971-4.964) -0.913(-4.166-2.340) 1.860(-4.826-6.346) 2.675(7-7.466-12.836) 5.381(-21.457-32.220) 1.4277-69(-12.826) 5.381(-21.457-32.220)	DFI	D KIRP ACC LGG KICH MESO PRAD PCPG TICCA SARC LIAD SKCM BLCA SKCM BRCA HNSC CHOL UCE CHOL CESCA COMP	pvalue <0.001	Hazard ratio 15.805(11.918-19.602) 8.527(8.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.225) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.288-4.770) 5.138(2.143-8.133) 17.625(8.856-28.394) 10.452(2.639-18.264) 2.486(0.591-4.381) 1.775(0.121-3.329) 2.134(0.148-4.120) 9.278(0.709-18.474) 1.733(-0.009-4.110) 5.746(-0.675-12.166) 3.528(-0.841-7.896) -1.652(-3.512-0.388) -1.652(-3.512-0.388) -1.552(-3.212-0.388) -1.552(-3.212-0.388) -1.552(-3.212-0.381) 1.759(-0.872-4.372) -1.46(-0.8	PFI
Off 0.100 0.101(-1.593-2.612) DLBC 0.661 2.505(-8.683-13.703) HNSC 0.817 -0.689(-6.393-5.188) OV 0.661 2.505(-8.683-13.703) BLCA 0.834 0.491(-4.087-5.069) OV 0.661 2.505(-8.683-13.703) ESCA 0.850 0.551(-5.151-6.253) OV 0.684 1.032(-3.943-6.007) READ 0.976 -0.271(-17.666-17.105) UUSC 0.897 -0.291(-2.624-2.042) WCR 0.991 -0.066(-11.945-11.813) -0.066(-11.945-11.813) UCS 0.971	C KIRP THCA LIHC BRCA BRCA MESO PAAD LUSC UCS PRAD CHOL LGG LUAD TGCT KICH COAD STAD UCEC ACC DLBC CESC	pvalue <0.001 0.003 0.012 0.044 0.064 0.075 0.133 0.332 0.332 0.401 0.425 0.447 0.482 0.512 0.586 0.606 0.6694 0.757 0.757	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-28.116) 5.141(-0.521-10.803) 2.742(-0.333-6.317) -6.612(-19.974-6.750) 3.038(-4.432-10.509) 0.874(-1.381-3.129) 1.981(-3.599-7.561) -10.388(-40.017-19.245) -2.503(-9.971-4.964) -0.9312(-4.165-2.340) 1.860(-4.226-6.546) 2.675(-7.486-12.836) 5.381(-21.457-32.220) 1.447(-6.991-9.855) 3.42(-29.2-21.277) 1.42(-6.921-9.855) 3.42(-29.2-21.277)	DFI	D KIRP KIRC LGG KICH MESO PRAD PCPG THCA SACC LUAD SKCM UWM UWM UWM UWCEC STAD GBM ESCA COAD THYM	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.000 0.000 0.000 0.000 0.000 0.005 0.035 0.035 0.045 0.045 0.045 0.045 0.045 0.045 0.047 0.047 0.516	Hazard ratio 15.805(11.918-19.602) 8.527(5.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.25) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.258-4.770) 5.138(2.143-8.133) 17.625(6.856-28.394) 10.452(2.593-48.394) 11.758(0.285-2.373) 1.725(0.121-3.329) 2.134(0.148-4.120) 9.278(0.709-18.478) 1.733(-0.009-4.117) 2.036(-0.099-4.117) 3.202(-0.099-4.1478) 1.526(-3.512-0.388) -1.599(-4.212-0.814) 1.750(-0.872-4.372) -1.446(-4.865-1972) -1.446(-4.865-1972) -1.446(-4.865-1972) -1.476(-4.772-2380)	PFI
Indice Outring	C KIRP THCA LIHC SARC BRCA MESO PRAD LUSC UCS PRAD LUSC UCS VCAD STAD UCEC ACC DLBC CCSC PCPG CV	pvalue <0.001 0.003 0.012 0.044 0.064 0.073 0.332 0.332 0.332 0.401 0.425 0.447 0.487 0.487 0.487 0.487 0.582 0.586 0.694 0.694 0.753 0.753	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.398(-4.432-10.089) 3.038(-4.432-10.089) 1.938(-3.3474-10.270)	DFI	D KIRP KIRC ACC LGG GG PRAD PAAD PCPG THCA SARC LLAD SARC LLAD SARC CHOL UCEC STAD GBM ESSA COAD THYM CESC	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001 0.001 0.000 0.000 0.035 0.035 0.048 0.051 0.048 0.052 0.013 0.116 0.185 0.191 0.407 0.516	Hazard ratio 15.805(11.918–19.602) 8.527(8.080–11.240) 11.401(7.025–15.777) 4.932(2.808-7.056) 15.216(8.208–7.056) 15.216(8.208–7.056) 15.216(8.208–7.056) 15.216(8.208–7.056) 15.216(8.208–7.056) 15.216(8.208–7.056) 15.216(8.208–7.056) 17.25(6.556–28.394) 10.452(2.539–18.264) 2.436(0.591–4.381) 1.778(0.282–3.273) 1.725(0.121–3.329) 2.134(0.148–4.120) 9.278(0.079–18.478) 1.733(-0.006–3.471) 2.006(-0.099–4.110) 5.746(-0.675–12.166) 3.528(-0.641–7.896) -1.556(-3.512–0.388) -1.556(-3.512–0.388) -1.556(-3.212–0.388) -1.556(-3.212–0.388) -1.569(-4.212–0.384) 1.750(-0.872–4.372) -1.746(-4.722–2.369) 1.145(-3.795–6.085)	PFI
DLCA 0.004 0.491 (=-0.07-5.099) TGCT 0.684 1.032(-3.943-6.007) ESCA 0.850 0.551(-5.151-6.253) US 0.807 -0.291(-2.624-2.042) READ 0.976 -0.271(-17.646-17.105) READ 0.899 -0.402(-6.537-5.833) KIRC 0.991 -0.066(-11.945-11.813) UCS 0.971 -0.106(-5.844-5.631)	C KIRP THCA SARC BRCA MESO PAAD LUSC PRAD CHOL LGG LUAD TGCT KICH COD CHOL CGS CACC DLBC CCSC CCSC CCSC CCSC CCSC CCSC CCSC C	pvalue <pre><0.001</pre> <pre><0.001</pre> <pre>0.003</pre> <pre>0.012</pre> <pre>0.044</pre> <pre>0.075</pre> <pre>0.133</pre> <pre>0.332</pre> <pre>0.332</pre> <pre>0.401</pre> <pre>0.425</pre> <pre>0.487</pre> <pre>0.487</pre> <pre>0.487</pre> <pre>0.487</pre> <pre>0.487</pre> <pre>0.586</pre> <pre>0.606</pre> 0.606 0.694 <pre>0.753</pre> 0.753 <pre>0.753</pre> <pre>0.753</pre> <pre>0.753</pre> <pre>0.754</pre>	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.038(-4.432-10.639) 3.038(-4.432-10.509) 0.874(-1.381-3.129) 1.981(-3.599-7.561) -10.388(-40.017-19.245) -2.503(-9.971-4.964) -0.913(-4.166-2.340) 1.860(-4.826-5.546) 5.381(-21.457-32.220) 1.447(-6.91-9.385) 5.381(-21.457-32.220) 1.447(-6.91-9.385) 5.381(-21.457-32.220) 3.45(-1.983-2.612) -0.992(-6.22)	DFI	D KIRP KIRC LGG KICH MESO PRAD PADD PADD PADD PADD SKCM BLCA UVM BRCA HINSC CHOL UCEC STAD GBM ESCA COAD THYM	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.000 0.010 0.000 0.010 0.035 0.035 0.0450000000000	Hazard ratio 15.805(11.918-19.692) 8.527(8.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216[8.206-22.225] 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.258-4.770) 5.138(2.143-8.133) 17.625(8.856-28.394) 10.452(2.639-18.264) 2.486(0.591-4.381) 1.778(0.282-3.273) 1.725(0.121-3.329) 2.134(0.148-4.120) 9.278(0.079-18.478) 1.733(-0.009-3.471) 2.006(-0.099-4.110) 5.746(-0.675-12.166) 3.528(-0.841-7.896) -1.562(-3.512-0.388) -1.599(-4.212-0.814) 1.750(-0.872-4.372) -1.446(-4.865-1.972) -1.176(-4.722-2.389) 1.145(-3.795-6.085) 2.505(-6.893-13.703)	PFI
ESCA 0.000 0.001 (T-0.151-0.203) LUSC 0.807 -0.291(-2.624-2.042) READ 0.976 -0.271(-17.664-71.105) READ 0.899 -0.402(-6.637-5.833) KIRC 0.991 -0.066(-11.945-11.813) UCS 0.971 -0.106(-5.844-5.631)	C KIRP THCA LIHC SARC BRCAO MESO PRAD LUSC UCS PRAD LUSC UCS PRAD CHOL LUSC UCS PRAD CHOL LUSC CHOL CHOL CCOL CCC STAD UCEC ACC CESC PCPG OV HISC	pvalue <0.001 0.003 0.012 0.044 0.075 0.133 0.332 0.401 0.425 0.447 0.487 0.492 0.581 0.582 0.581 0.582 0.582 0.582 0.584 0.694 0.737 0.753 0.753 0.753	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-28.855) 3.018(1.055-4.862) 3.018(1.055-4.862) 3.018(1.055-4.802) 1.247(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.038(-4.432-10.509) 0.874(-1.381-3.129) 1.981(-3.599-7.561) -0.138(-4.0407-19.245) -2.503(-9.971-4.964) -0.913(-4.168-2.340) 1.860(-4.825-8.546) 2.675(-7.486-12.836) 5.381(-21.457-32.220) 1.447(-6.991-9.835) 4.325(-22.622-31.272) -0.698(-6.593-5.198) -0.914(-4.93-6.192)	DFI	D KIRP KIRC ACC LGG KICH MESO PRAD PCPG THCA SKCM BLCA UCM BLCA UVM BLCA COAD CHNC CHNC COAD THYM CESC COAD COAC COAD COAD CESC COAD COAD CESC COAD COAD CESC COAD COAD CESC CESC C	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.009 0.010 0.035 0.035 0.045 0.051 0.062 0.075 0.113 0.116 0.185 0.185 0.185 0.185 0.516 0.6651	Hazard ratio 15.805(11.918-19.602) 8.527(5.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.25) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.288-4.770) 5.138(2.143-8.133) 17.625(6.856-28.394) 10.452(2.639-18.264) 2.436(6.0591-4.381) 1.778(0.0591-4.311) 1.778(0.0591-4.312) 2.134(0.148-4.120) 9.278(0.079-18.476) 1.733(-0.006-3.4711) 2.006(-0.099-4.110) 5.746(-0.675-12.166) 3.528(-0.841-7.396) -1.552(-3.512-0.388) -1.569(-4.212-0.814) 1.750(-0.872-4.372) -1.446(-4.865-1.972) -1.146(-4.865-1.972) -1.146(-7.955-0.052) 2.505(-6.693-13.703) 0.338(-1.191-1.388)	PFI
READ 0.899 -0.402(-6.637-5.833) KIRC 0.991 -0.066(-11.945-11.813) UCS 0.971 -0.106(-5.844-5.631)	C KIRP THCA LIHC SARC PRAD LUSC UCS PRAD LUSC UCS CHOL LGG LUAD TGCT KICH COAD STAD UCEC ACC DLBC CESC PCPG OV N	pvalue <0.001 0.003 0.012 0.044 0.064 0.073 0.332 0.332 0.332 0.401 0.425 0.447 0.487 0.487 0.487 0.487 0.487 0.582 0.566 0.694 0.737 0.753 0.753 0.753	Hazard ratio 18.135(12.242-24.027) 19.856(9.915-28.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.398(-3.474-10.270) 3.038(-4.432-10.509) 0.874(-1.381-3.129) 1.981(-3.599-7.561) -10.386(-4.017-19.245) -2.503(-9.971-4.964) -0.913(-4.166-2.340) 1.860(-4.826-8.546) 5.381(-21.487-3.220) 1.447(-6.991-3.885) 4.325(-22.622-31.272) 0.315(-1.983-2.612) -0.638(-6.533-5.139) 0.491(-4.087-5.069) 0.854(-1.983-2.612) -0.638(-6.533-5.139) 0.491(-4.087-5.069) 0.854(-2.563-5.198) 0.491(-4.087-5.069) 0.854(-2.563-5.198) 0.491(-4.087-5.069) 0.854(-2.563-5.198) 0.491(-4.087-5.069) 0.854(-2.563-5.198)	DFI	D KIRP ACC LGG KICH MESO PRAD PAAD PCPG THCA SARC LLIAD SARC LLIAD SARC UVM BRCA HNSC CHOL UCEC CHOL UCEC CON CON THYM	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001 0.001 0.000 0.003 0.035 0.035 0.048 0.051 0.065 0.116 0.185 0.191 0.651 0.665	Hazard ratio 15.805(11.918–19.662) 8.527(8.808–11.246) 11.401(7.025–15.777) 4.932(2.808–7.056) 15.216(8.206–22.225) 7.802(3.799–11.805) 6.752(3.204–10.300) 3.014(1.288–4.770) 5.138(2.143–8.133) 17.625(6.856–28.394) 10.452(2.639–18.248) 2.486(0.591–4.381) 1.776(0.282–3.273) 1.776(0.282–3.273) 1.7750(0.282–3.273) 1.7750(0.099–4.110) 5.744(-0.675–12.166) 3.528(-0.693–1.3703) -1.456(-4.865–1.972) -1.446(-4.865–1.972) -1.446(-4.865–1.972) -1.446(-4.865–1.972) -1.176(-4.722–2.369) 1.145(-3.795–6.085) 2.505(-6.633–1.3703) 0.338(-1.191–1.8688) 1.032(-3.943–6.007)	PFI ++++++++++++++++++++++++++++++++++++
UCS 0.9/1 -0.106(-5.844-5.631) -4-152-24-16-11-4-4 / 14-19-28-29 -4-152-24-16-11-4-4 / 14-19-28-29 -4-15-12-12-12-12-14-14-14-14-14-14-14-14-14-14-14-14-14-	C KIRP THOA LIHC BRCAO MESO PRAD LUSC UCS PRAD CHOL LGG LUAD TGCT KICH COAD STAD UCEC ACC PCPG OV HISCC	pvalue <0.001 0.003 0.012 0.044 0.075 0.133 0.332 0.401 0.425 0.541 0.425 0.541 0.586 0.606 0.696 0.696 0.696 0.696 0.737 0.733 0.738 0.738 0.738 0.738 0.738 0.738	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.308(-4.432-10.833-6.317) -6.612(-19.974-6.750) 3.038(-4.432-10.609) 0.874(-1.381-3.129) 1.981(-3.598-7.561) -2.503(-9.971-4.964) -0.931(-4.168-2.340) 1.860(-4.828-6.546) 5.381(-21.457-32.220) 1.447(-6.991-3.835) 4.325(-222-31.272) 0.315(-1.983-2.612) -0.698(-6.593-5.198) 0.451(-4.087-5.059) 0.551(-5.151-6.253) -0.74(-4.021-6.253	DFI	D KIRP KIRC LGG KICH MESO PRAD PADD PADD PADD PADD SKCM BLCA UVM BRCA HNSC UCC STAD GBM ESCA COAD THYM CSC DLBC OU COAD	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.000 0.010 0.020 0.035 0.035 0.035 0.045 0.051 0.0651 0.116 0.195 0.116 0.650 0.665	Hazard ratio 15.806(11.918-19.602) 8.527(5.008-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.006-22.25) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.258-4.770) 5.138(2.143-8.133) 17.625(6.856-28.394) 10.452(2.639-18.264) 2.486(0.591-4.381) 1.778(0.282-3.273) 1.725(0.121-3.329) 2.134(0.148-4.120) 9.278(0.079-18.478) 1.733(-0.009-4.110) 5.746(-0.079-18.478) 1.733(-0.009-4.147) 1.528(-3.512-0.386) -1.599(-4.212-0.314) 1.750(-0.872-4.372) -1.446(-4.865-1.972) -1.176(-4.722-2.369) 1.445(-3.795-6.065) 2.505(-6.803-13.703) 0.338(-1.191-1.868) 1.032(-3.943-6.007) -0.291(-2.624-2.042)	PFI ++++++++++++++++++++++++++++++++++++
-41-23.5 -42-11.5 -41-35 -42 -11.5 -41 و1 الم 1 و1 و1 و1 و2 و2 - الموال[العومي] الموال[العومي] (ما والم المراحي (ما و	C KIRP THCA LIHC SARC BRCA MESO PAD LUSC UCS PRAD LUSC UCS PRAD CHOL LUSC CHOL LUSC CHOL LUSC CHOL CHOL LUSC STAD UCEC ACC CESC PCPG OV HNSC BLCA ESCA READ	pvalue <0.001 <0.001 0.003 0.012 0.044 0.075 0.133 0.332 0.401 0.425 0.447 0.487 0.492 0.586 0.648 0.696 0.696 0.696 0.696 0.737 0.753 0.753 0.753 0.753 0.753 0.753	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-29.855) 3.018(1.055-4.982) 3.601(0.732-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.308(-4.432-410.270) 3.603(-4.803-12.008) 3.308(-4.432-410.270) 1.981(-3.899-7.561) -0.386(-40.017-19.245) 2.675(-7.486-12.340) 1.860(-4.262-6.546) 2.675(-7.486-12.340) 1.860(-4.262-6.546) 2.675(-7.486-12.340) 1.825(-22.223) 1.427(-6.991-3.835) 5.381(-21.457-32.220) 1.427(-6.991-3.835) 4.325(-22.622-31.272) 0.516(-5.515-6.253) 0.651(-5.151-6.253) -0.271(-17.646-17.105) -0.262(-1.045-12.215)	DFI	D KIRP KIRC ACC LGG CG PRAD PAAD PCPG FICCA SARC LLIAD SARC LLIAD SARC LLIAD SARC CH BLCA SARC CH BLCA SARC CH BLCA SARC CH SARC CH SARC CH SARC SAR	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001 0.000 0.010 0.020 0.035 0.035 0.048 0.062 0.073 0.116 0.165 0.165 0.191 0.407 0.516 0.664 0.664 0.664 0.684 0.807 0.899 0.001	Hazard ratio 15.805(11.918–19.602) 8.527(8.080–11.240) 11.401(7.025–15.777) 4.932(2.808–7.056) 15.216(8.206–22.225) 7.802(3.799–11.805) 6.752(3.204–10.300) 3.014(1.258–4.770) 5.138(2.143–8.133) 17.625(6.566–28.394) 10.452(2.639–18.264) 2.486(0.591–4.381) 1.776(0.222–3.273) 1.775(0.222–3.273) 1.725(0.121–3.329) 2.134(0.148–4.120) 9.278(0.079–18.478) 1.736(-0.663–12.166) 3.228(-0.841–7.896) 1.562(-3.512–0.388) -1.562(-3.512–0.388) -1.562(-3.512–0.388) -1.562(-3.512–0.388) -1.562(-3.4212–0.814) 1.756(-0.675–12.166) 3.228(-0.841–7.896) 1.599(-0.842–3.723) -1.169(-4.222–3.238) -1.169(-4.222–3.238) -1.446(-4.865–1.972) -1.176(-4.722–3.69) 1.145(-3.795–6.055) 2.505(-6.639–13.703) 0.332(-1.191–1.868) 1.032(-3.191–1.191–1.868) 1.032(-3.191–1.191–1.868) 1.032(-3.191–1.191–1.868) 1.032(-3.191–1.191–1.868) 1.032(-3.242–0.241) 0.42(-6.637–6.833) 0.42(-6.637–6.833)	PFI
	C KIRP THCA LIHC BRCAO PRAD LUSC PRAD LUSC PRAD LUSC PRAD LUSC LUSS PRAD LUSC CHOIL LUSC CHOIL C	pvalue <0.001 <0.001 0.003 0.014 0.064 0.075 0.133 0.332 0.332 0.401 0.425 0.447 0.487 0.487 0.487 0.487 0.487 0.487 0.582 0.566 0.694 0.733 0.753 0.753 0.753 0.814 0.850 0.976	Hazard ratio 18.135(12.242-24.027) 19.885(9.915-28.855) 3.018(1.055-4.982) 3.601(0.792-6.410) 2.347(0.060-4.634) 12.678(-0.760-26.116) 5.141(-0.521-10.803) 2.742(-0.833-6.317) -6.612(-19.974-6.750) 3.038(-4.033-12.008) 3.038(-4.432-10.698) 0.874(-1.381-3.129) 0.874(-1.381-3.129) 0.874(-1.381-3.129) 0.874(-1.381-3.129) 0.874(-1.381-3.229) 1.981(-3.599-7.561) -10.386(-40.017-19.245) 5.381(-21.487-3.220) 1.467(-4.826-3.240) 1.860(-4.991-9.885) 4.325(-22.622-31.272) 0.315(-1.983-2.612) -0.698(-6.539-5.188) 0.491(-4.087-5.069) 0.551(-5.151-6.5253) -0.271(-17.464-71.108) -0.066(-11.945-11.813)	DFI	D KIRP KIRC LGG KICH MESO PRAD PADD PADD PADD PADD SKCM BLCA UVM BRCA HNSC CHOL UCEC STAD GBM ESCA COAD THYM CESC DLSC READ	pvalue <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001 0.001 0.000 0.035 0.035 0.035 0.035 0.045 0.051 0.055 0.055 0.055 0.055 0.055 0.055 0.055 0.051 0.051 0.051 0.051 0.051 0.051 0.051 0.051 0.051 0.051 0.051 0.055 0.056 0.056 0.056 0.0570000000000	Hazard ratio 15.805(11.918-19.602) 8.527(8.808-11.246) 11.401(7.025-15.777) 4.932(2.808-7.056) 15.216(8.206-22.225) 7.802(3.799-11.805) 6.752(3.204-10.300) 3.014(1.288-4.770) 5.138(2.143-8.133) 17.625(6.856-28.394) 10.452(2.639-18.264) 10.452(2.639-18.264) 1.755(0.121-3.329) 2.134(0.148-4.120) 9.278(0.709-18.474) 1.733(-0.009-4.117) 2.036(-0.099-4.110) 5.746(-0.675-12.166) 3.528(-0.441-7.866) -1.552(-3.512-0.388) -1.552(-3.512-0.388) -1.552(-3.512-0.388) -1.552(-3.512-0.388) 1.145(-3.795-6.085) 2.550(-6.639-13.703) 0.338(-1.191-1.888) 1.032(-3.943-6.007) -0.291(-2.624-2.042) -0.402(-6.637-5.833) -0.106(-5.844-5.631)	PFI

FIGURE 6

The survival analysis of the SKA score. (A–D) Forest plots of the Cox analysis results of the SKA score across cancers. (A) OS, (B) disease-specific survival, (C) disease-free interval, and (D) progression-free interval.

tumor mutation burden (TMB) or microsatellite instability (MSI) values have emerged as strong markers in predicting the immune checkpoint inhibitor (ICI) response (41–43). The correlation between the SKA score and immunotherapy-related biomarkers (TMB and MSI) was further explored. The obtained results revealed that the SKA score was positively associated with TMB in 18 cancer types as well as MSI in 8 cancer types (Figures 10A, B). A significant correlation was observed between the SKA score and the TMB value of SKCM and BLCA, and we speculate that patients with high SKA scores are sensitive to immunotherapy in some cancer types.

To validate our hypothesis, we screened independent immunotherapy-related datasets from the SKCM (GSE91061 cohort) and BLCA (IMvigor210 cohort) datasets and computed the corresponding SKA score for each patient. We investigated whether the SKA score could predict patients' response to immune checkpoint blockade therapy based on two immunotherapy cohorts. In this study, a total of 24 melanoma samples were included in the GSE91061 cohort, and 348 BLCA samples were included in the IMvigor210 cohort. In both the anti-PD-1 cohort (GSE91061) and the anti-PD-L1 cohort (IMvigor210), patients with high SKA scores exhibited a significantly prolonged clinical response (Figures 11A, B) and markedly prolonged survival (Figures 11C, D). The significant therapeutic advantages and clinical response to anti-PD-1/L1 immunotherapy in patients with high SKA scores compared to those with low SKA scores were confirmed. Meanwhile, higher objective response rates were observed in the patients with high SKA scores than in those with low scores (Figures 11E, F). In addition, the predictive value of the SKA score in patients treated with anti-PD-1/L1 immunotherapy was superior to those of CTLA4 and PD-1/L1 (Figures 11G, H). This was another confirmation that patients with relatively high SKA scores were more suitable for immunotherapy. The



abovementioned results of a series of observations and validations implied that the SKA score may serve as a potential predictor of immunotherapy efficacy and chemotherapy efficacy for tumor therapy.

Immunohistochemistry

To further validate the results for SKA1/2/3 expression, immunohistochemical staining was performed. The results confirmed that SKA1/2/3 were higher in BC tissues than that in adjacent normal tissues, and SKA2 and SKA3 were higher in GC tissues than that in adjacent normal tissues (Figures 12A–J).

Identification of potential small molecule drugs

We first selected the top 30 small molecule drugs targeting SKA family genes ($|\mathbf{r}| > 0.3$). The obtained results revealed that the expression of SKA1/2/3 was positively associated with six cancer drugs but negatively correlated with the IC50 of 24 cancer drugs in GDSC (Figure S2A). This finding suggested that SKA family genes may be associated with tumor drug resistance in these six cancer drugs, such as trametinib and selumetinib. Our CTRP results also

showed that SKA3/1 was negatively correlated with the IC50 of 30 cancer drugs (Figure S2B). The lower was the IC50, the higher was the sensitivity to the drugs. These findings suggested that SKA family genes may be correlated with cancer sensitivity to multiple drugs.

Discussion

Cancer is a multifactorial disease that is influenced by multiple factors such as intracellular metabolism, evasion of immune surveillance, dysregulation of the cell cycle and inflammation (44). SKA1/2/3 contributes to the stability of mitotic metaphase (45). Several studies have suggested that SKA1/2/3 are involved not only in mitosis but also in apoptosis and tumor development. The dysregulation of SKA1/2/3 expression is a common phenomenon in malignant tumors, indicating that the SKA family is significantly related to malignancy. Currently, the function and mechanisms of SKA1/2/3 in the development and progression of certain cancers are being increasingly studied. Nevertheless, an understanding of the biological regulation of SKA family genes across cancers is lacking.

In this study, based on the ssGSEA method, we constructed the SKA score to quantify the SKA gene modification pattern of individual patients. We investigated the differential expression and potential prognostic value of the SKA score at the pan-cancer



level. In multiple cancer types, including BLCA, BRCA, CESC, CHOL, COAD, ESCA, HNSC, KIRC, KIRP, LIHC, LUAD, LUSC, PCPG, PRAD, READ, STAD, THCA, and UCEC, the SKA score was significantly elevated in tumor tissues compared with normal tissues. Results of Immunohistochemistry shown that SKA1/2/3 proteins were highly expressed in BC or GC tissues. Subsequent analysis showed that the SKA score was closely associated with tumor development and served as a strong risk factor for four survival outcomes (OS, DSS, PFI, and DFI) across 33 cancer types. The precise molecular mechanisms of SKA family genes in the development and progression of cancer are not completely clear and require additional studies. Nevertheless, the association between SKA family genes and some underlying tumor-related pathways may provide several valuable clues to understand the unique functional mechanisms in cancers. An in-depth analysis of SKA family genes confirmed that the SKA score was positively related to some cell cycle pathways and DNA replication in pancancer, including E2F targets, G2M checkpoint, MYC targets V1/ V2, mitotic spindle and DNA repair. The cell cycle is an evolutionarily conserved, highly coordinated process that is essential to cell growth. Aberrations of the cell cycle are a hallmark of cancer (46). Remarkably, cyclin-dependent kinase 1 (CDK1) is an important cell cycle regulator that is involved in the progression of the cell cycle (47). Interestingly, a previous study found that mutant SKA3 lacking CDK1 phosphorylation failed to locate KT (48). These findings, combined with our observations,

hint at the potential therapeutic target of the SKA family in cancer treatment.

The TME plays a role in promoting tumor development, metastasis, and resistance to chemotherapy and immunotherapy (49, 50). Given the importance of the TME in cancer, we next investigated the association between the SKA score and the TME, and the obtained results revealed that both the immune score and stromal score were negatively related to the SKA score, which indicated that cancer tissues with high SKA scores had significantly higher tumor purity and lower immune scores than those with low SKA scores. To validate these findings, we further analyzed the correlation of TME-related pathways with the SKA score based on a published paper, and the obtained results also showed that the SKA score was positively correlated with cell cycle pathways, DNA replication and repair pathways but negatively correlated with immune- or stromal-related pathways, which was consistent with the abovementioned findings. We next explored the association of the SKA score with immune cell infiltrates and observed that in 33 cancer types, the SKA score was closely associated with multiple immune cells, representing a state of immune-suppressed TME. The abovementioned results showed that patients with high SKA scores had poor immune cell infiltration, which may have contributed to the worse prognosis in cancer patients. Recent evidence from many studies has shown that immunotherapy, such as anti-PD-1/L1 therapy, has emerged as the most eye-catching treatment method for malignant tumors, and



the low response rate in the clinic is a great obstacle to the development of ICI therapy. In addition to PD-L1, high TMB and high MSI have been shown to be useful biomarkers for better immunotherapy response in cancer (41, 42, 51). High TMB levels lead to an increase in tumor neoantigens, which may trigger the immune system to attack the tumor. The reasons why high MSI and high TMB predict the response to immunotherapy are probably related because high MSI almost inevitably leads to a high TMB. To explore the correlation of the SKA score with ICI response, we conducted Spearman correlation analysis, and the obtained results showed that the TMB of 18 types of cancers as well as the MSI of 7 types of cancers, including SKCM and BLCA, were all positively correlated with the SKA score. Therefore, combining the abovementioned information, we speculate that patients with high SKA scores are sensitive to anti-PD-1/L1 treatment response. This

hypothesis was validated in independent cohorts of BLCA (IMvigor210) and SKCM (GSE91061) patients who received anti-PD-L1/PD-1 therapy. Thus, our results confirm that a high SKA score is closely related to the TME in a variety of cancers and that an elevated SKA score may serve as a novel tool in patients receiving anti-PD-1/L1 therapy, especially in patients with BLCA and SKCM. At the same time, our study also demonstrated a close association of SKA1/2/3 and drug sensitivity across cancers, suggesting a potential of SKA family genes and related pathways of biological functions as therapeutic targets.

Compared with previous studies on certain cancers, our study has three strengths. First, previous studies aimed to develop and validate a prognostic signature in certain cancers. Our study focused on pan-cancer data, making the SKA scoring system more universal and applicative. Second, compared with the studies assessing only



Correlation between the SKA score and TMB and MSI values. (A, B) Radar plot of the correlation between the SKA score and (A) TMB or (B) MSI. *P < 0.05, **P < 0.01, ***P < 0.001, ***P < 0.001.



FIGURE 11

The association between SKA score and immunotherapy response. (A, E) Differences in the m6Ascore among distinct anti-PD-1/L1 clinical response groups in the GSE91061 (A) and IMvigor210 cohorts (E). (B, F) Kaplan–Meier survival analysis of the SKA score in the GSE91061 (B) and IMvigor210 cohorts (F). (C, G) The percentage of responsive and progressive patients in the high- and low-SKA score groups in the GSE91061 (C) and IMvigor210 cohorts (G). (D, H) The predictive ability of the SKA score in patients receiving anti-PD-1/L1 therapy in the GSE91061 (D) and IMvigor210 cohorts (H). CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease. *P<0.05, ***P<0.001.

one survival outcome (usually OS), the SKA score in our study did not merely focus on four survival outcomes (OS, DSS, PFI, and DFI) across 33 cancer types but displayed a strong HR value for cancers. Third, we believe that this study was the first to explore the correlation of the SKA score with immunotherapy response based on the SKCM and BLCA cohort data, which had not been reported in certain cancer types.

Conclusion

Collectively, our results reveal that the SKA score is a robust risk factor for multiple cancer types and plays central roles in tumor development. A high SKA score was closely correlated with a variety of immune cells of the TME across multiple cancer types. Moreover, the SKA score can be used as a potential predictive biomarker for



patients receiving anti-PD-1/L1 therapy. Our comprehensive analysis highlighted the potential clinical value of SKA1/2/3-related strategies for cancer treatment, which highlights their significance for clinical practice and guidelines.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving human participants were reviewed and approved by the ethics committee of the First Affiliated Hospital of Guangxi Medical University (approval No.2022-E434-01). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

GD contributed to conception and design of the study. HW contributed to the experimental design and performed the

experiments. ZL and LH analyzed the data and wrote the first draft of the manuscript. JL, WY, WL, QL, XD, and HW wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Guangxi Science and Technology Project (No. 03202219002D).

Acknowledgments

The authors acknowledge GEO and UCSC Xena database for providing the platform for uploading the meaningful datasets. In addition, we thank WeChat public account "Shengxinxiaoketang" for providing technical advice on our bioinformatics analysis.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1012999/ full#supplementary-material

References

1. Auckland P, Clarke NI, Royle SJ, McAinsh AD. Congressing kinetochores progressively load ska complexes to prevent force-dependent detachment. *J Cell Biol* (2017) 216(6):1623–39. doi: 10.1083/jcb.201607096

2. Zhou L, Ouyang L, Chen K, Wang X. Research progress on KIF3B and related diseases. Ann Transl Med (2019) 7(18):492. doi: 10.21037/atm.2019.08.47

3. Sivakumar S, Gorbsky GJ. Phosphatase-regulated recruitment of the spindle- and kinetochore-associated (Ska) complex to kinetochores. *Biol Open* (2017) 6(11):1672–9. doi: 10.1242/bio.026930

4. Lange KI, Suleman A, Srayko M. Kinetochore recruitment of the spindle and kinetochore-associated (Ska) complex is regulated by centrosomal PP2A in caenorhabditis elegans. *Genetics* (2019) 212(2):509-22. doi: 10.1534/genetics.119.302105

5. Hu R, Wang MQ, Niu WB, Wang YJ, Liu YY, Liu LY, et al. SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling pathway. *Cancer Cell Int* (2018) 18:183. doi: 10.1186/s12935-018-0670-4

6. Chen Y, Zhao J, Jiao Z, Wang W, Wang D, Yu X, et al. SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma. *BMC Cancer* (2018) 18 (1):1240. doi: 10.1186/s12885-018-5119-6

7. Wang Y, Zhang C, Mai L, Niu Y, Wang Y, Bu Y. PRR11 and SKA2 gene pair is overexpressed and regulated by p53 in breast cancer. *BMB Rep* (2019) 52(2):157–62. doi: 10.5483/BMBRep.2019.52.2.207

8. Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. *Trends Cell Biol* (2015) 25(4):198–213. doi: 10.1016/j.tcb.2014.11.006

9. Coussens LM, Werb Z. Inflammation and cancer. *Nature* (2002) 420(6917):860– 7. doi: 10.1038/nature01322

10. Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, et al. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. *Gut* (2018) 67(10):1845–54. doi: 10.1136/gutjnl-2017-315201

11. Zeng D, Zhou R, Yu Y, Luo Y, Zhang J, Sun H, et al. Gene expression profiles for a prognostic immunoscore in gastric cancer. *Br J Surg* (2018) 105(10):1338–48. doi: 10.1002/bjs.10871

12. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell* (2013) 23(3):277–86. doi: 10.1016/j.ccr.2013.02.013

13. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. *Immunity* (2014) 41(1):49-61. doi: 10.1016/j.immuni.2014.06.010

14. Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, et al. Evaluation of PD-L1 expression and associated tumorinfiltrating lymphocytes in laryngeal squamous cell carcinoma. *Clin Cancer Res* (2016) 22(3):704–13. doi: 10.1158/1078-0432.CCR-15-1543

15. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. *Nature* (2017) 541(7637):321–30. doi: 10.1038/nature21349

16. Mizukoshi E, Kaneko S. Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol (2019) 12(1):52. doi: 10.1186/s13045-019-0742-5

17. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12(4):252-64. doi: 10.1038/nrc3239

18. Iñarrairaegui M, Melero I, Sangro B. Immunotherapy of hepatocellular carcinoma: facts and hopes. *Clin Cancer Res* (2018) 24(7):1518–24. doi: 10.1158/1078-0432.CCR-17-0289

SUPPLEMENTARY FIGURE 1

GSEA of SKA1/2/3 in TCGA pan-cancer. (A–P) The top 20 GSEA results of SKA1/2/3 in indicated tumor types from TCGA.

SUPPLEMENTARY FIGURE 2

Associations between SKA1/2/3 and drug sensitivity. Associations between SKA1/2/3 and drug sensitivity. **(A, B)** The relationship of drug sensitivity of GDSC (top 30) and CTRP (top 30) with SKA1/2/3 mRNA expression. Pearson correlation analysis was performed to obtain the correlation between gene mRNA expression and drug IC50. The P-value was adjusted by FDR. Blue bubbles represent negative correlations, red bubbles represent positive correlations, and the deeper is the color, the higher is the correlation.

SUPPLEMENTARY TABLE 2

Abbreviations and sample size for 33 cancer types

19. Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. *Nat Med* (2020) 26(6):909–18. doi: 10.1038/s41591-020-0839-y

20. Miao YR, Zhang Q, Lei Q, Luo M, Xie GY, Wang H, et al. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. *Adv Sci (Weinh)* (2020) 7(7):1902880. doi: 10.1002/advs.201902880

21. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. *Cancer Res* (2017) 77(21): e108–10. doi: 10.1158/1538-7445.AM2017-108

22. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* (2015) 43(7):e47. doi: 10.1093/nar/gkv007

23. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* (2019) 47(D1):D607–d613. doi: 10.1093/nar/gky1131

24. Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: a web server for gene set cancer analysis. *Bioinformatics* (2018) 34(21):3771-2. doi: 10.1093/bioinformatics/bty411

25. Huang L, Wu C, Xu D, Cui Y, Tang J. Screening of important factors in the early sepsis stage based on the evaluation of ssGSEA algorithm and ceRNA regulatory network. *Evol Bioinform Online* (2021) 17:11769343211058463. doi: 10.1177/11769343211058463

26. Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinf* (2013) 14:7. doi: 10.1186/1471-2105-14-7

27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U.S.A.* (2005) 102(43):15545–50. doi: 10.1073/pnas.0506580102

28. Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. *Cancer Immunol Res* (2019) 7(5):737–50. doi: 10.1158/2326-6066.CIR-18-0436

29. Qin Y, Conley AP, Grimm EA, Roszik J. A tool for discovering drug sensitivity and gene expression associations in cancer cells. *PloS One* (2017) 12(4):e0176763. doi: 10.1371/journal.pone.0176763

30. Han Y, Xu S, Cheng K, Diao C, Liu S, Zou W, et al. CENPF promotes papillary thyroid cancer progression by mediating cell proliferation and apoptosis. *Exp Ther Med* (2021) 21(4):401. doi: 10.3892/etm.2021.9832

31. Sun J, Huang J, Lan J, Zhou K, Gao Y, Song Z, et al. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. *Cancer Cell Int* (2019) 19:264. doi: 10.1186/s12935-019-0986-8

32. Kodama T, Marian TA, Lee H, Kodama M, Li J, Parmacek MS, et al. MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM. *Proc Natl Acad Sci U.S.A.* (2019) 116(47):23625–35. doi: 10.1073/pnas.1910413116

33. Zeng J, Hua S, Liu J, Mungur R, He Y, Feng J. Identification of core genes as potential biomarkers for predicting progression and prognosis in glioblastoma. *Front Genet* (2022) 13:928407. doi: 10.3389/fgene.2022.928407

34. Qin LT, Huang SW, Huang ZG, Dang YW, Fang YY, He J, et al. Clinical value and potential mechanisms of BUB1B up-regulation in nasopharyngeal carcinoma. *BMC Med Genomics* (2022) 15(1):272. doi: 10.1186/s12920-022-01412-8

35. Zhu LJ, Pan Y, Chen XY, Hou PF. BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation. *Oncol Lett* (2020) 19(5):3506–12. doi: 10.3892/ol.2020.11445

36. Zemach A, McDaniel IE, Silva P, Zilberman D. Genome-wide evolutionary analysis of eukaryotic DNA methylation. *Science* (2010) 328(5980):916–9. doi: 10.1126/ science.1186366

37. Feng S, Cokus SJ, Zhang X, Chen PY, Bostick M, Goll MG, et al. Conservation and divergence of methylation patterning in plants and animals. *Proc Natl Acad Sci U.S.A.* (2010) 107(19):8689–94. doi: 10.1073/pnas.1002720107

38. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science* (2018) 359(6382):1350–5. doi: 10.1126/science.aar4060

39. Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. *Cancer Immunol Immunother* (2017) 66(5):551–64. doi: 10.1007/s00262-017-1954-6

40. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. *Science* (2018) 359(6382):1361–5. doi: 10.1126/ science.aar6711

41. Phillips D, Matusiak M, Gutierrez BR, Bhate SS, Barlow GL, Jiang S, et al. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. *Nat Commun* (2021) 12(1):6726. doi: 10.1038/s41467-021-26974-6

42. Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy development and validation of the CRAFITY score. *J Hepatol* (2022) 76(2):353–63. doi: 10.1016/j.jhep.2021.09.035 43. Yu G, Pang Y, Merchant M, Kesserwan C, Gangalapudi V, Abdelmaksoud A, et al. Tumor mutation burden, expressed neoantigens and the immune microenvironment in diffuse gliomas. *Cancers (Basel)* (2021) 13(23):6092. doi: 10.3390/cancers13236092

44. Alexander SPH, Mathie A, Peters JA, Veale EL, Striessnig J, Kelly E, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: ion channels. *Br J Pharmacol* (2019) 176 Suppl 1(Suppl 1):S142–s228. doi: 10.1111/bph.14749

45. Sivakumar S, Janczyk P, Qu Q, Brautigam CA, Stukenberg PT, Yu H, et al. The human SKA complex drives the metaphase-anaphase cell cycle transition by recruiting protein phosphatase 1 to kinetochores. *Elife* (2016) 5:e12902. doi: 10.7554/eLife.12902

46. Dominguez-Brauer C, Thu KL, Mason JM, Blaser H, Bray MR, Mak TW. Targeting mitosis in cancer: emerging strategies. *Mol Cell* (2015) 60(4):524–36. doi: 10.1016/j.molcel.2015.11.006

47. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer* (2009) 9(3):153–66. doi: 10.1038/nrc2602

48. Zhang Q, Sivakumar S, Chen Y, Gao H, Yang L, Yuan Z, et al. Ska3 phosphorylated by Cdk1 binds Ndc80 and recruits ska to kinetochores to promote mitotic progression. *Curr Biol* (2017) 27(10):1477–1484.e4. doi: 10.1016/j.cub.2017.03.060

49. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat Med* (2018) 24(5):541–50. doi: 10.1038/s41591-018-0014-x

50. da Silva PHR, Borges BC, Uehara IA, Soldi LR, de Araújo RA, Silva MJB, et al. Chemokines and the extracellular matrix: set of targets for tumor development and treatment. *Cytokine* (2021) 144:155548. doi: 10.1016/j.cyto.2021.155548

51. Li R, Han D, Shi J, Han Y, Tan P, Zhang R, et al. Choosing tumor mutational burden wisely for immunotherapy: a hard road to explore. *Biochim Biophys Acta Rev Cancer* (2020) 1874(2):188420. doi: 10.1016/j.bbcan.2020.188420